Universal donor cells
Genetic modification of cells with CRISPR/Cas9 technology to introduce deletions and tolerogenic factors enhances immune evasion and survival, addressing allogeneic rejection and post-engraftment issues in universal donor cells.
Patent Information
- Application Number
- JP2021512530
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-09-07
- Filing Date
- 2019-09-07
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2039-09-07
AI Technical Summary
Existing methods for creating universal donor cells face challenges in overcoming allogeneic rejection and ensuring cell survival post-engraftment, as they may trigger immune responses and are susceptible to natural killer cell elimination, with potential safety concerns from non-specific cleavage during genetic modification.
Genetic modification of cells involves introducing deletions and/or insertions in MHC-I or MHC-II genes, combined with tolerogenic factors like PD-L1 or HLA-E, and survival factors such as MANF, using CRISPR/Cas9 technology to enhance immune evasion and survival, while minimizing off-target effects.
The modified cells demonstrate increased immune evasion and survival, reducing allogeneic rejection and post-engraftment challenges, making them suitable for diverse transplantation applications.
Smart Images

Figure 0007581183000016 
Figure 0007581183000017 
Figure 0007581183000018
Abstract
Description
[Technical field]
[0001] Related Applications This application claims the benefit of U.S. Provisional Patent Application No. 62 / 728,529, filed Sep. 7, 2018, the disclosure of which is incorporated herein by reference in its entirety.
[0002] The present invention relates to the field of gene editing and, in some embodiments, to genetic modification to create cells that are compatible with multiple subjects, e.g., universal donor cells. [Background technology]
[0003] Various approaches have been proposed to overcome allorejection of transplanted or engrafted cells, including HLA matching, blocking pathways that induce T cell activation by antibodies, the use of cocktails of immunosuppressants, and autologous cell therapy. Another strategy to attenuate graft rejection involves minimizing allogeneic differences between transplanted or engrafted cells and the recipient. Human leukocyte antigens (HLA), molecules expressed on the cell surface that are encoded by genes located in the human major histocompatibility complex on chromosome 6, are the major mediators of immune rejection. Mismatches of a single HLA gene between donor and subject can trigger strong immune responses (Fleischhauer K. et al. "Bone marrow-allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA-B44", N Engl J Med., 1990, 323:1818-1822). HLA genes are classified into MHC class I (MHC-I) and MHC class II (MHC-II). MHC-I genes (HLA-A, HLA-B, and HLA-C) are expressed in almost all tissue types and present "non-self" antigen-processed peptides to CD8+ T cells, thereby promoting their activation into cytolytic CD8+ T cells. Transplanted or engrafted cells expressing "non-self" MHC-I molecules will trigger a strong cellular immune response directed against these cells, ultimately leading to their elimination by activated cytolytic CD8+ T cells. MHC-I proteins are essentially associated with beta-2-microglobulin (B2M) in the endoplasmic reticulum, which is essential for the formation of functional MHC-I molecules on the cell surface.
[0004] In contrast to the widespread cellular expression of MHC-I genes, the expression of MHC-II genes is restricted to antigen-presenting cells such as dendritic cells, macrophages, and B cells. HLA antigen genes are the most polymorphic genes observed in the human genome (Rubinstein P., "HLA matching for bone marrow transplantation--how much is enough?" N Engl J Med., 2001, 345:1842-1844). The creation of "universal donor" cells compatible with any HLA genotype provides an alternative strategy that may solve the associated economic costs of existing methodologies for immune rejection and immune evasion.
[0005] To generate such a lineage of universal donor cells, one prior approach has functionally disrupted the expression of MHC-I and MHC-II class genes. This can be activated, for example, by genetic disruption of both gene alleles encoding the MHC-I light chain, B2M. The resulting B2M KO cell line and its derivatives would be expected to exhibit a significant reduction in surface MHC-I and thus reduced immunogenicity to allogeneic CD8+ T cells. A transcription activator-like effector nuclease (TALEN) targeting approach has been used to generate B2M-deficient hESC lines by deletion of a few nucleotides in exon 2 of the B2M gene (Lu, P. et al., "Generating hypoimmunogenic human embryonic stem cells by the disruption of beta 2-microglobulin", Stem Cell Rev. 2013, 9:806-813). Although B2M-targeted hESC lines appeared to be surface HLA-I deficient, they were still found to contain mRNA specific for B2M and MHC-I. B2M and MHC-I mRNAs were expressed at levels comparable to those of non-targeted hESCs (both constitutive and IFN-g inducible). Thus, there is concern that these TALEN B2M-targeted hESC lines may express residual cell surface MHC-I that may be sufficient to cause immune rejection, as observed in B2M2 / 2 mouse cells that also express B2M mRNA (Gross, R. and Rappuoli, R. "Pertussis toxin promoter sequences involved in modulation", Proc Natl Acad Sci, 1993, 90:3913-3917).Although TALEN B2M targeted hESC lines were not tested for off-target cleavage events, the occurrence of non-specific cleavage when using TALENs remains a significant issue that is believed to pose a major safety concern for their clinical use (Grau, J. et al. "TALEN offer: genome-wide TALEN off-target prediction", Bioinformatics, 2013, 29:2931-2932; Guilinger JP et al. "Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity", Nat Methods 2014, 11:429-435). Furthermore, in another report, IPS cells were generated that avoided allorecognition by knocking out the first B2M allele and knocking in the HLA-E gene with the second B2M allele, resulting in surface expression of HLA-E dimers or trimers in the absence of surface expression of HLA-A, HLA-B, or HLA-C (Gornalusse, Gget al., "HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells", Nature Biotechnology, 2017, 35, 765-773).
[0006] A potential limitation of some of the above strategies is that MHC class I negative cells are susceptible to lysis by natural killer (NK) cells because HLA molecules function as major ligand inhibitors for NK cells. Host NK cells have been shown to eliminate transplanted or engrafted B2M- / - donor cells, and a similar phenomenon occurs in vitro with MHC class I negative human leukemia lines (Bix, M. et al., "Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice", Nature, 1991, 349, 329-331; Zarcone, D. et al., "Human leukemia-derived cell lines and clones as models for mechanistic analysis of natural killer cell-mediated cytotoxicity", Cancer Res. 1987, 47, 2674-2682). Therefore, there is a need to improve on previous methods to create universal donor cells that can avoid immune responses, and to create cells that can survive after engraftment. As described herein, cell survival after engraftment can be mediated by many other pathways that do not depend on allo-rejection, such as hypoxia, reactive oxygen species, nutrient deprivation, and oxidative stress. Also, as described herein, genetic transfer of survival factors (genes and / or proteins) can help cells survive after engraftment. As described herein, universal donor cell lines can combine properties that address both allo-rejection and survival after engraftment. Summary of the Invention [Means for solving the problem]
[0007] In some aspects, the disclosure encompasses methods of generating a universal donor cell. The first method includes genetically modifying a cell by (i) introducing a deletion and / or insertion of at least one base pair in the genome of the cell at a site within or near at least one gene encoding one or more of the MHC-I or MHC-II human leukocyte antigens or components or transcriptional regulators of the MHC-I or MHC-II complexes; and (ii) introducing an insertion of at least one polynucleotide encoding a tolerogenic factor at a site in the genome of the cell that partially overlaps, completely overlaps, or is contained within the site of (i), thereby generating a universal donor cell. The second method comprises genetically modifying a cell by (i) introducing a deletion and / or insertion of at least one base pair in the genome of the cell at a site within or near at least one gene encoding one or more of the MHC-I or MHC-II human leukocyte antigens or components or transcriptional regulators of the MHC-I or MHC-II complexes; and (ii) introducing an insertion of at least one polynucleotide encoding a tolerogenic factor at a safe harbor locus in the genome of the cell, thereby generating a universal donor cell. In some embodiments, the universal donor cell has increased immune evasion and / or cell survival compared to an unmodified cell.
[0008] In some embodiments, the at least one gene encoding one or more MHC-I or MHC-II human leukocyte antigens, or components or transcriptional regulators of the MHC-I or MHC-II complexes, is an MHC-I gene selected from HLA-A, HLA-B, or HLA-C, an MHC-II gene selected from HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, or HLA-DR, or a gene selected from B2M, NLRC5, CIITA, RFX5, RFXAP, or RFXANK.
[0009] In some embodiments, the at least one polynucleotide encoding a tolerogenic factor is one or more polynucleotides encoding one or more of PD-L1, HLA-E, HLA-G, CTLA-4, or CD47. In some embodiments, the at least one polynucleotide encoding a tolerogenic factor is operably linked to an exogenous promoter. In some embodiments, the exogenous promoter is a constitutive, inducible, time-specific, tissue-specific, or cell type-specific promoter, optionally, the exogenous promoter is a CMV, EFla, PGK, CAG, or UBC promoter.
[0010] In some embodiments, the (i) deletion and / or insertion is in or near B2M and the (ii) insertion is in a polynucleotide encoding PD-L1 or HLA-E.
[0011] In some embodiments, the method further comprises introducing at least one genetic modification that increases or decreases the expression of at least one survival factor relative to unmodified cells.In some embodiments, the at least one genetic modification that increases or decreases the expression of at least one survival factor is the insertion of a polynucleotide encoding MANF, which increases the expression of MANF relative to unmodified cells; or the deletion and / or insertion of at least one base pair in or near the gene encoding ZNF143, TXNIP, FOXO1, or JNK, which decreases or eliminates the expression of ZNF143, TXNIP, FOXO1, or JNK relative to unmodified cells.In some embodiments, the polynucleotide encoding MANF is inserted into a safe harbor locus or into a gene belonging to MHC-I, MHC-II, or a transcriptional regulator of MHC-I or MHC-II.
[0012] In some embodiments, genetically modifying the cell comprises delivering at least one RNA-guided endonuclease system to the cell. In some embodiments, the at least one RNA-guided endonuclease system is a CRISPR system comprising a CRISPR nuclease and a guide RNA. In some embodiments, the CRISPR nuclease is Cas9, Cpf1, a homologue thereof, a modified version thereof, a codon-optimized version thereof, or any combination thereof. In some embodiments, the CRISPR nuclease is S. pyogenes Cas9. In some embodiments, the CRISPR nuclease comprises an N-terminal nuclear localization signal (NLS) and / or a C-terminal NLS. In some embodiments, the CRISPR nuclease and the guide RNA are present in a weight ratio of 1:1.
[0013] In some embodiments, the deletion and / or insertion in (i) is in or near the B2M locus, and the insertion in (ii) is a polynucleotide encoding PD-L1. In some embodiments, the guide RNA used for (i) and (ii) comprises a nucleotide sequence comprising at least one of SEQ ID NOs: 1-3 or SEQ ID NOs: 35-44. In some embodiments, the polynucleotide encoding PD-L1 is flanked by (a) a nucleotide sequence having sequence homology to a region located to the left of the site in (i) and (b) a nucleotide sequence having sequence homology to a region located to the right of the site in (i). In some embodiments, the polynucleotide encoding PD-L1 is inserted into the B2M locus within 50 base pairs of the site in (i). In some embodiments, (a) in the polynucleotide consists essentially of the nucleotide sequence of SEQ ID NO: 13, and (b) in the polynucleotide consists essentially of the nucleotide sequence of SEQ ID NO: 19. In some embodiments, the polynucleotide encoding PD-L1 is operably linked to an exogenous promoter, optionally the exogenous promoter is a CAG promoter.
[0014] In some embodiments, the cell is a mammalian cell, optionally the cell is a human cell. In some embodiments, the cell is a stem cell, optionally the stem cell is a pluripotent stem cell (PSC), an embryonic stem cell (ESC), an adult stem cell (ASC), an induced pluripotent stem cell (iPSC), or a hematopoietic stem or progenitor cell (HSPC). In some embodiments, the cell is a differentiated cell or a somatic cell.
[0015] In some embodiments, the universal donor cells can differentiate into lineage-restricted progenitor cells or fully differentiated somatic cells. In some embodiments, the lineage-restricted progenitor cells are pancreatic endodermal progenitor cells, pancreatic endocrine progenitor cells, mesenchymal progenitor cells, muscle progenitor cells, blast cells, or neural progenitor cells. In some embodiments, the fully differentiated somatic cells are endocrine cells, such as pancreatic beta cells, epithelial cells, endodermal cells, macrophages, hepatocytes, adipocytes, kidney cells, blood cells, or immune system cells.
[0016] In other aspects, the disclosure encompasses a plurality of universal donor cells produced by any of the methods disclosed herein. In some embodiments, the plurality of universal donor cells can be maintained for a time and under conditions sufficient for the cells to undergo differentiation.
[0017] In a further aspect, the disclosure provides compositions of cells comprising: (i) at least one deletion within or near at least one gene encoding one or more MHC-I and MHC-II human leukocyte antigens, or a component or transcriptional regulator of the MHC-I or MHC-II complex; and (ii) at least one insertion of a polynucleotide encoding at least one tolerogenic factor at a site partially overlapping, completely overlapping, or contained within the site of the gene deletion of (i).
[0018] In an additional aspect, the disclosure provides a method of administering any of the universal donor cells disclosed herein to a subject in need of treatment. In some embodiments, the method comprises obtaining or having obtained a plurality of universal donor cells as disclosed herein after differentiation into lineage-restricted progenitor cells or fully differentiated somatic cells; and administering the lineage-restricted progenitor cells or fully differentiated somatic cells to the subject. The present invention also provides a method of obtaining cells for administration to a subject in need. The method comprises (i) obtaining or having obtained any of the universal donor cells disclosed herein; and (ii) maintaining the universal donor cells for a time and under conditions sufficient for the cells to differentiate into lineage-restricted progenitor cells or fully differentiated somatic cells. In some embodiments, the lineage-restricted progenitor cells are pancreatic endoderm progenitor cells, pancreatic endocrine progenitor cells, mesenchymal progenitor cells, muscle progenitor cells, blast cells, or neural progenitor cells. In some embodiments, the fully differentiated somatic cells are endocrine cells such as pancreatic beta cells, epithelial cells, endodermal cells, macrophages, hepatocytes, adipocytes, kidney cells, blood cells, or immune system cells. In some embodiments, the subject is a human who has, is suspected of having, or is at risk for a disease, and the disease can be a genetically inherited disease.
[0019] While the present disclosure is susceptible to various modifications and alternative forms, specific embodiments thereof have been shown by way of example in the drawings and will herein be described in detail. It is to be understood, however, that the drawings and detailed description set forth herein are not intended to limit the disclosure to the particular embodiments disclosed, but on the contrary, are intended to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the present disclosure as defined by the appended claims.
[0020] Other features and advantages of the present invention will become apparent in the following detailed description of preferred embodiments of the invention, which proceeds with reference to the accompanying drawings. [Brief description of the drawings]
[0021] [Figure 1A-1C] Specific gene editing strategies for immune evasion are provided. Figure 1A is a table listing exemplary modifications for immune evasion in designated cell types. Figure 1B provides exemplary strategies for modifying the B2M locus. Figure 1C provides exemplary strategies for modifying the HLA-A, HLA-B / C, and CIITA loci. [Diagram 2] A portion of the B2M gene (SEQ ID NO: 6) is shown, as well as the locations of the gRNAs (B2M-1, B2M-2, and B2M-3) for targeting exon 1. The locations of the PCR primers (B2MF2 and B2MR2) are also shown. [Figure 3A-3C] Results are shown from screening of B2M gRNAs in the TC1133 iPSC cell line. Figure 3A is a graph showing the indel (insertion + deletion) frequency of each B2M gRNA. B2M-1 gRNA yielded an indel frequency of 2.5% ± 1.1% (n = 2). B2M-2 gRNA yielded an indel frequency of 87.6% ± 14.1% (n = 2). B2M-3 gRNA yielded an indel frequency of 63.9% ± 0.9% (n = 2). Figures 3B and 3C are graphs outlining the distribution of indel results for B2M-2 (Figure 3B) and B2M-3 (Figure 3C) gRNAs. [Figure 4A-4B] Figure 4 shows the results of B2M knockout (KO) in iPSCs using B2M-2 gRNA. Figure 4A is a graph outlining the distribution of indel results for B2M-2 gRNA in iPSCs. Figure 4B shows clones homozygous for B2M knockout (KO) ("homo") and clones heterozygous for B2M KO ("hetero"). [Diagram 5]
[0036] Figure 1 shows evaluation of B2M KO iPSC clones. All three B2M KO clones tested showed reduced B2M mRNA expression relative to wild-type or unmodified cells. [Figures 6A-6D]Figure 6 shows expression of B2M and HLA-ABC in B2M KO iPSC clones after 47 hours of treatment with interferon-gamma. Figure 6A shows expression in wild type cells. Figure 6B shows expression in B2M KO clone C4. Figure 6C shows expression in B2M KO clone C9. Figure 6D shows expression in B2M KO clone C12. [Figure 7A-7D] The pluripotency of B2M KO iPSC clones is demonstrated through evaluation of the expression levels of SSEA-4 and TRA-1-60. Figure 7A shows expression in wild type cells. Figure 7B shows expression in B2M KO clone C4. Figure 7C shows expression in B2M KO clone C9. Figure 7D shows expression in B2M KO clone C12. [Figure 8] 1 shows TIDE analysis of B2M gRNA cleavage in CyT49 cells. B2M gRNA-1, -2, or -3 were tested. [Figure 9A-9B] Flow cytometry assessment of B2M expression in WT CyT49 cells (FIG. 9A) and edited CyT49 cells (FIG. 9B) both with and without IFN-γ is shown. [Figure 10] Figure 2 shows the plasmid map of the B2M-CAGGS-PD-L1 donor vector for HDR. [Figure 11] Flow cytometry analysis of pluripotency of B2M KO+PD-L1 KI CyT49 stem cells. Derived clones were >99% double positive for OCT4 and SOX2, two transcription factors essential for pluripotency. IgG was used as a negative control. [Figure 12A-12B] Flow cytometry analysis of stem cell clones derived from WT CyT49 (Figure 12A) and B2M KO / PD-L1 KI (Figure 12B). WT cells upregulate B2M expression in response to IFNγ. B2M KO / PD-L1 KI clones express PD-L1 abundantly and do not express B2M with or without IFNγ treatment. NT-1 = untreated. INTG-1 = cells treated with 50ng / mL IFNγ for 48 hours. [Figure 13]1 shows the plasmid map of the B2M-CAGGS-HLA-E donor vector for HDR. [Figure 14] Flow cytometry analysis of pluripotency of B2M KO / HLA-E KI CyT49 stem cells. Derived clones were >99% double positive for OCT4 and SOX2, two transcription factors essential for pluripotency. IgG was used as a negative control. [Figure 15] Flow cytometry analysis of WT CyT49 and B2M KO / HLA-E KI CyT49 stem cell clones. WT cells upregulate HLA-A, B, C expression in response to IFNγ. B2M KO / HLA-E KI clones do not express HLA-A, B, C with or without IFNγ treatment. IFNγ=50ng / mL. Cells were treated with IFNγ for 48 hours. [Figure 16] Flow cytometry analysis for HLA-E expression of B2M KO / HLA-E KI CyT49 stem cell clones. Unedited clones were used as controls for HLA-E expression. [Figure 17] Flow cytometry for FOXA2 and SOX17 in stage 1 (definitive endoderm) cells differentiated from wild-type, PD-L1 KI / B2M KO, or B2MKO hESCs. [Figure 18] Quantitative percentages of FOXA2 and SOX17 expression in stage 1 (definitive endoderm) cells differentiated from wild-type, PD-L1 KI / B2M KO, or B2M KO cells are shown. [Figure 19] Quantitative percentages of CHGA, PDX1, and NKX6.1 expression in stage 4 (PEC) cells differentiated from wild-type, B2M KO, PD-L1 KI / B2M KO (V1A), or HLA-E KI / B2M KO (V2A) cells are shown. [Figure 20] Shown is a heterogeneous population of stage 4 (PEC) cells. [Figure 21A-21B]Shown is selected gene expression over the differentiation time course in cells differentiated from wild-type, PD-L1KI / B2MKO, or B2MKO cells (Figure 21A) and cells differentiated from B2M KO / HLA-E KI(V2A) cells (Figure 21B). [Fig. 22A-22F] Figure 22 shows B2M and PD-L1 expression at the PEC stage in cells differentiated from wild-type, PD-L1 KI / B2M KO, or B2M KO cells. Figure 22A shows B2M expression in wild-type cells. Figure 22B shows B2M expression in B2M KO cells. Figure 22C shows B2M expression in PD-L1 KI / B2M KO cells. Figure 22D shows PD-L1 expression in wild-type cells. Figure 22E shows PD-L1 expression in B2M KO cells. Figure 22F shows PD-L1 expression in PD-L1 KI / B2M KO cells. [Fig. 23A-23F] Figure 23 shows MHC class I and class II expression at the PEC stage in cells differentiated from wild-type, PD-L1 / B2M KO, or B2M KO cells. Figure 23A shows MHC class I expression in wild-type cells. Figure 23B shows MHC class I expression in B2M KO cells. Figure 23C shows MHC class I expression in PD-L1 KI / B2M KO cells. Figure 23D shows MHC class II PD-L1 expression in wild-type cells. Figure 23E shows MHC class II expression in B2M KO cells. Figure 23F shows MHC class II expression in PD-L1 KI / B2M KO cells. [Fig. 24A-24D]Figure 24 shows flow cytometry analysis for T cell activation using CFSE proliferation assay. Human primary CD3+ T cells were co-incubated with PECs derived from WT, B2M KO, or B2M KO / PD-L1 KI CyT49 clones. Figure 24A shows activation in wild type cells. Figure 24B shows activation in PD-L1 KI / B2M KO cells. Figure 24C shows activation in B2M KO cells. Figure 24D summarizes T cell activation in different cells. One-way ANOVA (α=0.05 with Dunnett's multiple comparison test) with "CFSE-T alone" set as control. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. ns=non-significant. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0022] I. Definition Deletion: As used herein, the term "deletion", which may be used interchangeably with the term "gene deletion" or "knockout", generally refers to a genetic modification in which a site or region of genomic DNA is removed by any molecular biological method, such as those described herein, for example, by delivering an endonuclease and at least one gRNA to the site of genomic DNA. Any number of nucleotides may be deleted. In some embodiments, the deletion comprises removal of at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20, or at least 25 nucleotides. In some embodiments, the deletion comprises removal of 10-50, 25-75, 50-100, 50-200, or more than 100 nucleotides. In some embodiments, the deletion comprises removal of the entire target gene, e.g., the B2M gene. In some embodiments, the deletion comprises removal of a portion of the target gene, e.g., all or part of the promoter and / or coding sequence of the B2M gene. In some embodiments, the deletion involves the removal of a transcriptional regulator, e.g., the promoter region of the target gene. In some embodiments, the deletion involves the removal of all or a portion of a coding region such that the product normally expressed by the coding region is no longer expressed, is expressed in a truncated form, or is expressed at a reduced level. In some embodiments, the deletion results in a decrease in expression of the gene relative to an unmodified cell.
[0023] Endonuclease: As used herein, the term "endonuclease" generally refers to an enzyme that cleaves phosphodiester bonds in a polynucleotide. In some embodiments, the endonuclease specifically cleaves phosphodiester bonds in a DNA polynucleotide. In some embodiments, the endonuclease is a zinc finger nuclease (ZFN), a transcription activator-like effector nuclease (TALEN), a homing endonuclease (HE), a meganuclease, a MegaTAL, or a CRISPR-associated endonuclease. In some embodiments, the endonuclease is an RNA-guided endonuclease. In certain aspects, the RNA-guided endonuclease is a CRISPR nuclease, for example, a type II CRISPR Cas9 endonuclease or a type V CRISPR Cpf1 endonuclease. In some embodiments, the endonuclease is Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas100, Csy1, Csy2, Csy3, Csel, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr2, Csx12, Csx13, Csx14, Csx15, Csx16, Csx17, Csx18, Csx19, Csx10, Csx11, Csx12, Csx13, Csx14, Csx15, Csx16, Csx17, Csx18, Csx19, Csx19, Csx10 ... 3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, or Cpf1 endonuclease, or a homolog thereof, a recombinant naturally occurring molecule thereof, a codon-optimized version thereof, or a modified version thereof, or a combination thereof. In some embodiments, the endonuclease may introduce one or more single-stranded breaks (SSBs) and / or one or more double-stranded breaks (DSBs).
[0024] Genetic modification: As used herein, the term "genetic modification" generally refers to a site of genomic DNA that has been genetically edited or engineered using any molecular biology method, such as the methods described herein, for example, by delivering an endonuclease and at least one gRNA to the site of the genomic DNA. Examples of genetic modifications include insertions, deletions, duplications, inversions, and translocations, and combinations thereof. In some embodiments, the genetic modification is a deletion. In some embodiments, the genetic modification is an insertion. In other embodiments, the genetic modification is an insertion-deletion mutation (or indel) in which the reading frame of the target gene is shifted to result in a modified gene product or no gene product.
[0025] Guide RNA (gRNA): As used herein, the term "guide RNA" or "gRNA" generally refers to a short ribonucleic acid that can interact with, e.g., bind to, an endonuclease and bind or hybridize to a target genomic site or region. In some embodiments, the gRNA is a single-molecule guide RNA (sgRNA). In some embodiments, the gRNA may include a spacer extension region. In some embodiments, the gRNA may include a tracrRNA extension region. In some embodiments, the gRNA is single stranded. In some embodiments, the gRNA comprises naturally occurring nucleotides. In some embodiments, the gRNA is a chemically modified gRNA. In some embodiments, the chemically modified gRNA is a gRNA that comprises at least one nucleotide having a chemical modification, e.g., a 2'-O-methyl sugar modification. In some embodiments, the chemically modified gRNA comprises a modified nucleic acid backbone. In some embodiments, the chemically modified gRNA comprises a 2'-O-methyl-phosphorothioate residue. In some embodiments, the gRNA may be pre-complexed with a DNA endonuclease.
[0026] Insertion: As used herein, the term "insertion", which may be used interchangeably with the terms "gene insertion" or "knock-in", generally refers to a genetic modification in which a polynucleotide is introduced or added to a site or region of genomic DNA by any molecular biological method, such as the methods described herein, such as by delivering an endonuclease and at least one gRNA to the site of the genomic DNA. In some embodiments, the insertion may occur within or near a site of the genomic DNA that was the site of a previous genetic modification, such as a deletion or an insertion-deletion mutation. In some embodiments, the insertion occurs at a site of the genomic DNA that partially overlaps, completely overlaps, or is contained within the site of a previous genetic modification, such as a deletion or an insertion-deletion mutation. In some embodiments, the insertion occurs at a safe harbor locus. In some embodiments, the insertion comprises the introduction of a polynucleotide encoding a protein of interest. In some embodiments, the insertion comprises the introduction of a polynucleotide encoding a tolerogenic factor. In some embodiments, the insertion comprises the introduction of a polynucleotide encoding a survival factor. In some embodiments, the insertion comprises the introduction of an exogenous promoter, such as a constitutive promoter, such as a CAG promoter. In some embodiments, the insertion comprises the introduction of a polynucleotide that encodes a non-coding gene. Generally, the polynucleotide to be inserted is flanked by sequences that have substantial sequence homology (e.g., homology arms) with the genomic DNA at or near the site of insertion.
[0027] Major Histocompatibility Complex Class I (MHC-I): As used herein, the term "Major Histocompatibility Complex Class I" or "MHC-I" generally refers to a class of biomolecules found on the cell surface of all nucleated cells in mammals, e.g., vertebrates, including humans; and function to present non-self or foreign antigenic peptides, e.g., proteins, from within the cell (i.e., cytosol) to cytotoxic T cells, e.g., CD8+ T cells, to stimulate an immune response. In some embodiments, the MHC-I biomolecule is an MHC-I gene or MHC-I protein. Complex formation of the MHC-I protein with the beta-2 microglobulin (B2M) protein is required for cell surface expression of all MHC-I proteins. In some embodiments, reducing expression of MHC-I human leukocyte antigen (HLA) relative to unmodified cells comprises a reduction (or reduction) in expression of the MHC-I gene. In some embodiments, reducing expression of MHC-I human leukocyte antigen (HLA) relative to unmodified cells comprises a reduction (or reduction) in cell surface expression of the MHC-I protein. In some embodiments, the MHC-I biomolecule is HLA-A (NCBI Gene ID No.: 3105), HLA-B (NCBI Gene ID No.: 3106), HLA-C (NCBI Gene ID No.: 3107), or B2M (NCBI Gene ID No.: 567).
[0028] Major Histocompatibility Complex Class II (MHC-II): As used herein, the term "Major Histocompatibility Complex Class II" or "MHC-II" generally refers to a class of biological molecules typically found on the cell surface of antigen-presenting cells in vertebrates, including mammals, e.g., humans; and function to present peptides, e.g., proteins, of non-self or foreign antigens from the outside (extracellular) of the cell to cytotoxic T cells, e.g., CD8+ T cells, to stimulate an immune response. In some embodiments, the antigen-presenting cell is a dendritic cell, macrophage, or B cell. In some embodiments, the MHC-II biological molecule is an MHC-II gene or MHC-II protein. In some embodiments, reducing expression of MHC-II human leukocyte antigen (HLA) relative to unmodified cells comprises a reduction (or reduction) in expression of the MHC-II gene. In some embodiments, reducing expression of MHC-II human leukocyte antigen (HLA) relative to unmodified cells comprises a reduction (or reduction) in cell surface expression of the MHC-II protein. In some embodiments, the MHC-II biomolecule is HLA-DPA (NCBI Gene ID No.: 3113), HLA-DPB (NCBI Gene ID No.: 3115), HLA-DMA (NCBI Gene ID No.: 3108), HLA-DMB (NCBI Gene ID No.: 3109), HLA-DOA (NCBI Gene ID No.: 3111), HLA-DOB (NCBI Gene ID No.: 3112), HLA-DQA (NCBI Gene ID No.: 3117), HLA-DQB (NCBI Gene ID No.: 3119), HLA-DRA (NCBI Gene ID No.: 3122), or HLA-DRB (NCBI Gene ID No.: 3123).
[0029] Polynucleotide: As used herein, the term "polynucleotide," which may be used interchangeably with the term "nucleic acid," generally refers to a biological molecule that comprises two or more nucleotides. In some embodiments, the polynucleotide comprises at least 2, at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 100, at least 200, at least 250, at least 500, or any number of nucleotides. The polynucleotide may be a DNA or RNA molecule or a hybrid DNA / RNA molecule. The polynucleotide may be single-stranded or double-stranded. In some embodiments, the polynucleotide is a site or region of genomic DNA. In some embodiments, the polynucleotide is an endogenous gene contained within the genome of an unmodified cell or a universal donor cell. In some embodiments, the polynucleotide is an exogenous polynucleotide that is not integrated into genomic DNA. In some embodiments, the polynucleotide is an exogenous polynucleotide that is integrated into genomic DNA. In some embodiments, the polynucleotide is a plasmid or an adeno-associated viral vector. In some embodiments, the polynucleotide is a circular or linear molecule.
[0030] Safe harbor locus: As used herein, the term "safe harbor locus" generally refers to any location, site, or region of genomic DNA that can accommodate gene insertion at that location, site, or region without adverse effects on the cell. In some embodiments, a safe harbor locus is an intragenic or extragenic region. In some embodiments, a safe harbor locus is a region of genomic DNA that is typically transcriptionally silent. In some embodiments, a safe harbor locus is the AAVS1 (PPP1R12C), ALB, Angptl3, ApoC3, ASGR2, CCR5, FIX (F9), G6PC, Gys2, HGD, Lp (a), Pcsk9, Serpinal, TF, or TTR locus. In some embodiments, a safe harbor locus is described in Sadelain, M. et al., "Safe harbours for the integration of new DNA in the human genome", Nature Reviews Cancer, 2012, Vol 12, pp. 51-58.
[0031] Safety switch: As used herein, the term "safety switch" generally refers to a biological molecule that causes a cell to undergo apoptosis. In some embodiments, the safety switch is a protein or a gene. In some embodiments, the safety switch is a suicide gene. In some embodiments, the safety switch, e.g., herpes simplex virus thymidine kinase (HSV-tk), causes a cell to undergo apoptosis by metabolizing a prodrug, e.g., ganciclovir. In some embodiments, the presence of an overexpressed safety switch on its own causes a cell to undergo apoptosis. In some embodiments, the safety switch is a p53-based molecule, HSV-tk, or inducible caspase-9.
[0032] Subject: As used herein, the term "subject" refers to a mammal. In some embodiments, the subject is a non-human primate or rodent. In some embodiments, the subject is a human. In some embodiments, the subject has, is suspected of having, or is at risk for a disease or disorder. In some embodiments, the subject has one or more symptoms of a disease or disorder.
[0033] Survival factor: As used herein, the term "survival factor" generally refers to a protein (e.g., expressed by a polynucleotide as described herein) that, when increased or decreased in a cell, allows the cell, e.g., universal donor cell, to survive at a higher rate after transplantation or engraftment into a host subject relative to an unmodified cell. In some embodiments, the survival factor is a human survival factor. In some embodiments, the survival factor is a member of a critical pathway involved in cell survival. In some embodiments, the critical pathway involved in cell survival has an effect on hypoxia, reactive oxygen species, nutrient deprivation, and / or oxidative stress. In some embodiments, genetic modification, e.g., deletion or insertion, of at least one survival factor allows the universal donor cell to survive for a longer period than an unmodified cell after engraftment, e.g., at least 1.05-fold, at least 1.1-fold, at least 1.25-fold, at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, or at least 50-fold longer. In some embodiments, the survival factor is ZNF143 (NCBI Gene ID No.: 7702), TXNIP (NCBI Gene ID No.: 10628), FOXO1 (NCBI Gene ID No.: 2308), JNK (NCBI Gene ID No.: 5599), or MANF (NCBI Gene ID No.: 7873). In some embodiments, the survival factor is inserted into the cell, e.g., the universal donor cell. In some embodiments, the survival factor is deleted from the cell, e.g., the universal donor cell. In some embodiments, the insertion of a polynucleotide encoding MANF allows the cell, e.g., the universal donor cell, to survive at a higher rate after transplantation or engraftment into a host subject relative to an unmodified cell. In some embodiments, the deletion or insertion-deletion mutation in or near the ZFN143, TXNIP, FOXO1, or JNK gene allows the cell, e.g., the universal donor cell, to survive at a higher rate after transplantation or engraftment into a host subject relative to an unmodified cell.
[0034] Tolerogenic factor: As used herein, the term "tolerogenic factor" generally refers to a protein (e.g., expressed by a polynucleotide as described herein) that, when increased or decreased in a cell, enables the cell, e.g., universal donor cell, to inhibit or avoid immune rejection at a higher rate after transplantation or engraftment into a host subject relative to unmodified cells. In some embodiments, the tolerogenic factor is a human tolerogenic factor. In some embodiments, genetic modification of at least one tolerogenic factor (e.g., insertion or deletion of at least one tolerogenic factor) enables the cell, e.g., universal donor cell, to inhibit or avoid immune rejection at least 1.05-fold, at least 1.1-fold, at least 1.25-fold, at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, or at least 50-fold higher after engraftment than unmodified cells. In some embodiments, the tolerogenic factor is HLA-E (NCBI Gene ID No: 3133), HLA-G (NCBI Gene ID No: 3135), CTLA-4 (NCBI Gene ID No: 1493), CD47 (NCBI Gene ID No: 961), or PD-L1 (NCBI Gene ID No: 29126). In some embodiments, the tolerogenic factor is inserted into the cell, e.g., the universal donor cell. In some embodiments, the tolerogenic factor is deleted from the cell, e.g., the universal donor cell. In some embodiments, the insertion of a polynucleotide encoding HLA-E, HLA-G, CTLA-4, CD47, and / or PD-L1 enables the cell, e.g., the universal donor cell, to inhibit or avoid immune rejection following transplantation or engraftment into a host subject.
[0035] MHC-I or MHC-II transcriptional regulator: As used herein, the term "MHC-I or MHC-II transcriptional regulator" generally refers to a biomolecule that regulates, e.g., increases or decreases, the expression of MHC-I and / or MHC-II human leukocyte antigens. In some embodiments, the biomolecule is a polynucleotide, e.g., a gene, or a protein. In some embodiments, the MHC-I or MHC-II transcriptional regulator will increase or decrease the cell surface expression of at least one MHC-I or MHC-II protein. In some embodiments, the MHC-I or MHC-II transcriptional regulator will increase or decrease the expression of at least one MHC-I or MHC-II gene. In some embodiments, the transcriptional regulator is CIITA (NCBI Gene ID No: 4261) or NLRC5 (NCBI Gene ID No: 84166). In some embodiments, the deletion or reduction of expression of CIITA or NLRC5 reduces the expression of at least one MHC-I or MHC-II gene.
[0036] Universal donor cells: As used herein, the term "universal donor cells" generally refers to genetically modified cells that are less susceptible to allorejection during cell transplantation and / or demonstrate increased survival after transplantation relative to unmodified cells. In some embodiments, a genetically modified cell as described herein is a universal donor cell. In some embodiments, a universal donor cell has increased immune evasion and / or cell survival compared to unmodified cells. In some embodiments, a universal donor cell has increased cell survival compared to unmodified cells. In some embodiments, a universal donor cell may be a stem cell. In some embodiments, a universal donor cell may be an embryonic stem cell (ESC), an adult stem cell (ASC), an induced pluripotent stem cell (iPSC), or a hematopoietic stem or progenitor cell (HSPC). In some embodiments, a universal donor cell may be a differentiated cell. In some embodiments, a universal donor cell may be a somatic cell (e.g., an immune system cell). In some embodiments, a universal donor cell is administered to a subject. In some embodiments, the universal donor cells are administered to a subject having, suspected of having, or at risk of having a disease. In some embodiments, the universal donor cells can differentiate into lineage-restricted progenitor cells or fully differentiated somatic cells. In some embodiments, the lineage-restricted progenitor cells are pancreatic endoderm progenitor cells, pancreatic endocrine progenitor cells, mesenchymal progenitor cells, muscle progenitor cells, blast cells, or neural progenitor cells. In some embodiments, the fully differentiated somatic cells are endocrine cells, such as pancreatic beta cells, epithelial cells, endodermal cells, macrophages, hepatocytes, adipocytes, kidney cells, blood cells, or immune system cells.
[0037] Unmodified cell: As used herein, the term "unmodified cell" refers to a cell that has not been subjected to genetic modification, including polynucleotides or genes encoding MHC-I, MHC-I, MHC-I or MHC-II transcriptional regulators, survival factors, and / or immune tolerogenic factors. In some embodiments, the unmodified cell may be a stem cell. In some embodiments, the unmodified cell may be an embryonic stem cell (ESC), an adult stem cell (ASC), an induced pluripotent stem cell (iPSC), or a hematopoietic stem or progenitor cell (HSPC). In some embodiments, the unmodified cell may be a differentiated cell. In some embodiments, the unmodified cell may be selected from a somatic cell (e.g., an immune system cell, e.g., a T cell, e.g., a CD8+ T cell). When a universal donor cell is compared "against an unmodified cell," the universal donor cell and the unmodified cell are the same cell type or share a common parental cell line, e.g., a universal donor iPSC is compared against an unmodified iPSC.
[0038] In or near a gene: As used herein, the term "in or near a gene" refers to a site or region of genomic DNA that is an intronic or extronic component of the gene or is located adjacent to the gene. In some embodiments, a site of genomic DNA is within a gene if it comprises at least a portion of an intron or exon of the gene. In some embodiments, a site of genomic DNA located near a gene may be at the 5' or 3' end of the gene (e.g., the 5' or 3' end of the coding region of the gene). In some embodiments, a site of genomic DNA located near a gene may be a promoter region or a repressor region that regulates expression of the gene. In some embodiments, a site of genomic DNA located near a gene may be on the same chromosome as the gene. In some embodiments, a site or region of genomic DNA is near a gene if it is within 50 Kb, 40 Kb, 30 Kb, 20 Kb, 10 Kb, 5 Kb, 1 Kb, or closer to the 5' or 3' end of the gene (e.g., the 5' or 3' end of the coding region of the gene).
[0039] II. Genome editing methods Genome editing generally refers to a process of modifying the nucleotide sequence of a genome, preferably in a precise or predetermined manner. In some embodiments, genome editing methods as described herein, such as CRISPR-endonuclease systems, may be used to genetically modify cells as described herein, for example, to generate universal donor cells. In some embodiments, genome editing methods as described herein, such as CRISPR-endonuclease systems, may be used to genetically modify cells as described herein, for example, to introduce at least one genetic modification in or near at least one gene that reduces the expression of one or more MHC-I and / or MHC-II human leukocyte antigens or other components of the MHC-I or MHC-II complexes to unmodified cells; to introduce at least one genetic modification that increases the expression of at least one polynucleotide encoding a tolerogenic factor to unmodified cells; and / or to introduce at least one genetic modification that increases or decreases the expression of at least one gene encoding a survival factor to unmodified cells.
[0040] Examples of genome editing methods described herein include those using site-specific nucleases that cleave deoxyribonucleic acid (DNA) at precise target locations in the genome, thereby creating single- or double-stranded DNA breaks at specific locations in the genome. Such breaks can be repaired, and are regularly repaired, by natural endogenous cellular processes such as homology-directed repair (HDR) and non-homologous end joining (NHEJ), as described in Cox et al., "Therapeutic genome editing: prospects and challenges", Nature Medicine, 2015, 21(2), 121-31. These two major DNA repair processes consist of a family of alternative pathways. NHEJ is the direct joining of DNA ends resulting from double-stranded breaks, which may involve the deletion or addition of nucleotide sequences, and may disrupt or enhance the expression of genes. HDR utilizes a homologous sequence, or donor sequence, as a template to insert a predetermined DNA sequence at the break point. The homologous sequence may be present in the endogenous genome, such as a sister chromatid. Alternatively, the donor sequence may be an exogenous polynucleotide such as a plasmid, single-stranded oligonucleotide, double-stranded oligonucleotide, duplex oligonucleotide, or virus that has regions of high homology with the nuclease cleavage locus (e.g., left and right homology arms), but may also contain additional sequences or sequence changes, including deletions, that may be incorporated into the target locus to be cleaved. A third repair mechanism may be microhomology-mediated end joining (MMEJ), also called "alternative NHEJ," which is similar to NHEJ in that the genetic consequences are that small deletions and insertions may occur at the cleavage site.MMEJ can utilize a few base pairs of homologous sequences flanking the DNA break site to promote a more favorable DNA end-joining repair outcome, and recent reports have further elucidated the molecular mechanisms of this process; see, e.g., Cho and Greenberg, Nature, 2015, 518, 174-76; Kent et al., Nature Structural and Molecular Biology, 2015, 22(3):230-7; Mateos-Gomez et al., Nature, 2015, 518, 254-57; Ceccaldi et al., Nature, 2015, 528, 258-62. In some cases, it may be possible to predict the repair outcome based on the analysis of potential microhomologies at the site of the DNA break.
[0041] Each of these genome editing mechanisms can be used to create desired genetic modifications.The step in genome editing process can be to create one or two DNA breaks, the latter being double-strand breaks or two single-strand breaks at the target locus as the vicinity of the intended mutation site.This can be achieved through the use of endonucleases as described and shown herein.
[0042] CRISPR endonuclease system CRISPR-endonuclease system is a naturally occurring defense mechanism in prokaryotes that has been repurposed as an RNA-guided DNA targeting platform for gene editing. CRISPR system includes type I, II, III, IV, V, and VI systems. In some embodiments, CRISPR system is type II CRISPR / Cas9 system. In other embodiments, CRISPR system is type V CRISPR / Cprf system. CRISPR system relies on DNA nuclease, such as Cas9, and two non-coding RNAs, crisprRNA (crRNA) and transactivating RNA (tracrRNA), to target DNA cleavage.
[0043] The crRNA typically facilitates sequence recognition and specificity of the CRISPR-endonuclease complex through Watson-Crick base pairing with a sequence of about 20 nucleotides (nt) in the target DNA. Varying the sequence of the 5' 20 nt in the crRNA allows targeting of the CRISPR-endonuclease complex to a specific locus. The CRISPR-endonuclease complex only binds to DNA sequences that contain a sequence that matches the first 20 nt of the single guide RNA (sgRNA) if the target sequence is followed by a specific short DNA motif (having the sequence NGG) called the protospacer adjacent motif (PAM).
[0044] TracrRNA hybridizes to the 3' end of crRNA to form an RNA duplex structure and is bound by the endonuclease to form a catalytically active CRISPR-endonuclease complex, which can then cleave the target DNA.
[0045] When the CRISPR-endonuclease complex binds to DNA at the target site, two independent nuclease domains within the endonuclease each cut one of the DNA strands three bases upstream of the PAM site, leaving a double-stranded break (DSB) in which both strands of DNA terminate in base pairs (blunt ends).
[0046] In some embodiments, the endonuclease is Cas9 (CRISPR associated protein 9). In some embodiments, the Cas9 endonuclease is from Streptococcus pyogenes, although other Cas9 homologs may be used, such as S. aureus Cas9, N. meningitidis Cas9, S. thermophilus CRISPR1 Cas9, S. thermophilus CRISPR3 Cas9, or T. denticola Cas9. In other cases, the CRISPR endonuclease is Cpf1, such as L. bacterium ND2006 Cpf1 or Acidaminococcus sp. BV3L6 Cpf1. In some embodiments, the endonuclease is Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas100, Csy1, Csy2, Csy3, Csel, Cse2, Csc1, Csc2, Csa5, Csn2, Csx13, Csx14, Csx15, Csx16, Csx17, Csx18, Csx19, Csx100, Csx101, Csx102, Csx103, Csx104, Csx105, Csx106, Csx107, Csx108, Csx109, Csx110, Csx111, Csx112, Csx113, Csx114, Csx115, Cs sm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, or Cpf1 endonuclease. In some embodiments, wild-type variants may be used. In some embodiments, modified versions of the aforementioned endonucleases (e.g., homologs thereof, recombinant naturally occurring molecules thereof, codon-optimized versions thereof, or modified versions thereof) may be used.
[0047] The CRISPR nuclease may be linked to at least one nuclear localization signal (NLS). The at least one NLS may be located at or within 50 amino acids of the amino terminus of the CRISPR nuclease, and / or the at least one NLS may be located at or within 50 amino acids of the carboxy terminus of the CRISPR nuclease.
[0048] Exemplary CRISPR / Cas polypeptides include the Cas9 polypeptides as published in Fonfara et al., "Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems", Nucleic Acids Research, 2014, 42:2577-2590. The nomenclature of CRISPR / Cas genes has undergone extensive rewriting since the discovery of Cas genes. Fonfara et al. also provide PAM sequences for Cas9 polypeptides from various species.
[0049] Zinc Finger Nucleases Zinc finger nucleases (ZFNs) are modular proteins composed of an engineered zinc finger DNA binding domain linked to the catalytic domain of the type II endonuclease FokI. Because FokI functions only as a dimer, a pair of ZFNs must be designed to bind to identical target "half-site" sequences on opposite DNA strands with precise spacing to allow the formation of a catalytically active FokI dimer. Dimerization of the FokI domain, which has no sequence specificity by itself, generates a DNA double-strand break between the ZFN half-sites as the initiating step of genome editing.
[0050] The DNA binding domain of each ZFN is typically composed of 3-6 zinc fingers of abundant Cys2-His2 structure, each finger primarily recognizing a triplet of nucleotides on one strand of the target DNA sequence, although strand-crossing interactions with the fourth nucleotide may also be important. Modification of the amino acids of the fingers at positions that make important contacts with the DNA will modify the sequence specificity of a given finger. Thus, a 4-finger zinc finger protein will selectively recognize a 12 bp target sequence, which is composed of the triplet preference conferred by each finger, although the triplet preference can be influenced to various degrees by adjacent fingers. An important aspect of ZFNs is that they can be easily retargeted to most genomic addresses by simply modifying individual fingers. In most applications of ZFNs, proteins with 4-6 fingers are used, each recognizing 12-18 bp. Thus, a pair of ZFNs will typically recognize a combined target sequence of 24-36 bp, not including the typical 5-7 bp spacer between the half sites. The binding sites may be further separated by a larger spacer, including 15-17 bp. Target sequences of this length are expected to be unique in the human genome, and repeated sequences or gene homologs are assumed to be excluded during the design process. Nevertheless, the protein-DNA interactions of ZFNs are not absolute in their specificity, and off-target binding and cleavage phenomena occur as heterodimers between two ZFNs, or as homodimers of one or the other ZFN. The latter possibility was effectively eliminated by engineering the dimerization interface of the FokI domain to create "plus" and "minus" variants, also known as obligatory heterodimer variants, that can simply dimerize with each other and not with themselves. By forcing the obligatory heterodimers, homodimer formation is prevented. This greatly enhanced the specificity of ZFNs, as well as any other nucleases employing these FokI variants.
[0051] A variety of ZFN-based systems have been described in the art, modifications of which are regularly reported, and numerous references describe the rules and parameters used to guide the design of ZFNs; see, e.g., Segal et al., Proc Natl Acad Sci, 1999 96(6):2758-63; Dreier B et al., J Mol Biol., 2000, 303(4):489-502; Liu Q et al., J Biol Chem., 2002, 277(6):3850-6; Dreier et al., J Biol Chem., 2005, 280(42):35588-97; and Dreier et al., J Biol Chem. 2001, 276(31):29466-78.
[0052] Transcription activator-like effector nucleases (TALENs) TALENs represent another form of modular nuclease in which, similar to ZFNs, an engineered DNA-binding domain is linked to a FokI nuclease domain, and a pair of TALENs work in tandem to achieve targeted DNA cleavage. The main difference with ZFNs is the nature of the DNA-binding domain and the associated target DNA sequence recognition properties. TALEN DNA-binding domains are derived from TALE proteins, which were first described in the plant pathogenic microorganism Xanthomonas sp. TALEs are composed of a tandem array of 33-35 amino acid repeats, each of which recognizes a single base pair in a target DNA sequence typically up to 20 bp long, giving a total target sequence length of up to 40 bp. The nucleotide specificity of each repeat is determined by a repeating variable dinucleotide (RVD) that includes two amino acids at positions 12 and 13. The bases guanine, adenine, cytosine and thymine are primarily recognized by four RVDs: Asn-Asn, Asn-Ile, His-Asp and Asn-Gly, respectively. This makes the recognition code much simpler than zinc fingers, and therefore has advantages over zinc fingers in nuclease design. Nevertheless, like ZFNs, the protein-DNA interactions of TALENs are not absolute in their specificity, and TALENs also benefit from the use of obligate heterodimer variants of the FokI domain, which reduces off-target activity.
[0053] Additional variants of the FokI domain that are inactivated in catalytic function have been created. If one member of either a TALEN or ZFN pair contains an inactive FokI domain, only single-stranded DNA cleavage (nicking) will occur at the target site, not DSBs. This result is comparable to the use of CRISPR / Cas9 or CRISPR / Cpf1 "nickase" mutants (in which one of the Cas9 cleavage domains is inactivated). DNA nicks can be used to drive genome editing by HDR, but less efficiently than DSBs. The main advantage is that off-target nicks are repaired quickly and accurately, unlike DSBs that are prone to NHEJ-mediated misrepair.
[0054] Various TALEN-based systems have been described in the art, and modifications thereof are reported regularly; see, e.g., Boch, Science, 2009 326(5959):1509-12; Mak et al., Science, 2012, 335(6069):716-9; and Moscou et al., Science, 2009, 326(5959):1501. The use of TALEN based "Golden Gate" platform, or cloning scheme, has been described by several groups; see, e.g., Cermak et al., Nucleic Acids Res., 2011, 39(12):e82; Li et al., Nucleic Acids Res., 2011, 39(14):6315-25; Weber et al., PLoS One., 2011, 6(2):e16765; Wang et al., J Genet Genomics, 2014, 41(6):339-47.; and Cermak T et al., Methods Mol Biol., 2015 1239:133-59.
[0055] Homing endonucleases Homing endonucleases (HEs) are sequence-specific endonucleases with long recognition sequences (14-44 base pairs) that cleave DNA with high specificity (often at unique sites in the genome). There are at least six known families of HEs as classified by their structures, including GIY-YIG, His-Cis box, HNH, PD-(D / E)xK, and Vsr-like, that are derived from a wide range of hosts, including eukaryotes, protists, bacteria, archaea, cyanobacteria, and phages. Similar to ZFNs and TALENs, HEs can be used to cause DSBs at target loci as the first step in genome editing. In addition, some natural and engineered HEs cleave only a single strand of DNA, thereby functioning as site-specific nickases. The broad target sequences of HEs and the specificity they offer make them attractive candidates for causing site-specific DSBs.
[0056] Various HE-based systems have been described in the art and modifications thereof are regularly reported; see, e.g., the reviews by Steentoft et al., Glycobiology, 2014, 24(8):663-80; Belfort and Bonocora, Methods Mol Biol., 2014, 1123:1-26; and Hafez and Hausner, Genome, 2012, 55(8):553-69.
[0057] MegaTAL / Tev-mTALEN / MegaTev As further examples of hybrid nucleases, the MegaTAL and Tev-mTALEN platforms use a fusion of the DNA-binding domain of a TALE and a catalytically active HE to exploit both the tunable DNA binding and specificity of the TALE and the cleavage sequence specificity of the HE; see, e.g., Boissel et al., Nucleic Acids Res., 2014, 42:2591-2601; Kleinstiver et al., G3, 2014, 4:1155-65; and Boissel and Scharenberg, Methods Mol. Biol., 2015, 1239:171-96.
[0058] In a further variant, the MegaTev structure is a fusion of Meganuclease (Mega) with the nuclease domain from GIY-YIG homing endonuclease I-TevI (Tev). The two active sites are located about 30 bp apart on the DNA substrate, generating two DSBs with incompatible sticky ends; see, for example, Wolfs et al., Nucleic Acids Res., 2014, 42, 8816-29. It is expected that other combinations of existing nuclease-based approaches will be developed and will be useful for achieving the targeted genome modification described herein.
[0059] dCas9-FokI or dCpf1-FokI and other nucleases Combining the structural and functional properties of the above nuclease platforms provides an additional approach to genome editing that may overcome some of the inherent shortcomings. As an example, CRISPR genome editing systems usually use a single Cas9 endonuclease to cause DSBs. Targeting specificity is promoted by a 20 or 24 nucleotide sequence in the guide RNA that undergoes Watson-Crick base pairing with the target DNA (plus an additional 2 bases in the adjacent NAG or NGG PAM sequence in the case of Cas9 from S. pyogenes). Although such sequences are long enough to be unique in the human genome, the specificity of the RNA / DNA interaction is not absolute, and significant randomness may be tolerated, especially in the 5' half of the target sequence, effectively reducing the number of bases that promote specificity. One solution to this has been to completely inactivate the catalytic function of Cas9 or Cpf1 (retaining only the RNA-guided DNA binding function) and fuse the FokI domain to the inactivated Cas9 instead; see, e.g., Tsai et al., Nature Biotech, 2014, 32:569-76; and Guilinger et al., Nature Biotech., 2014, 32:577-82. Because FokI must dimerize to become catalytically active, two guide RNAs are required to tether two FokI fusions in close proximity to form dimers and cleave DNA. This essentially doubles the number of bases in the combined target site, thereby increasing the stringency of targeting by CRISPR-based systems.
[0060] As a further example, fusion of a TALE DNA binding domain to a catalytically active HE such as I-TevI takes advantage of both the tunable DNA binding and specificity of the TALE, as well as the cleavage sequence specificity of I-TevI, with the hope that off-target cleavage may be further reduced.
[0061] RNA-guided endonucleases An RNA-guided endonuclease system as used herein can include an amino acid sequence having at least 10%, at least 15%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 100% amino acid sequence identity to a wild-type exemplary endonuclease, such as Cas9 from S. pyogenes (SEQ ID NO: 8 of US Patent Application Publication No. 2014 / 0068797 or Sapranauskas et al., Nucleic Acids Res, 39(21):9275-9282 (2011)). The endonuclease may comprise at least 70, 75, 80, 85, 90, 95, 97, 99, or 100% identity over 10 contiguous amino acids with a wild-type endonuclease (e.g., Cas9 from S. pyogenes, supra). The endonuclease may comprise up to 70, 75, 80, 85, 90, 95, 97, 99, or 100% identity over 10 contiguous amino acids with a wild-type endonuclease (e.g., Cas9 from S. pyogenes, supra). The endonuclease may comprise at least 70, 75, 80, 85, 90, 95, 97, 99, or 100% identity to a wild-type endonuclease (e.g., Cas9 from S. pyogenes, supra) over 10 consecutive amino acids in the HNH nuclease domain of the endonuclease. The endonuclease may comprise up to 70, 75, 80, 85, 90, 95, 97, 99, or 100% identity to a wild-type endonuclease (e.g., Cas9 from S. pyogenes, supra) over 10 consecutive amino acids in the HNH nuclease domain of the endonuclease.The endonuclease may comprise at least 70, 75, 80, 85, 90, 95, 97, 99, or 100% identity to a wild-type endonuclease (e.g., Cas9 from S. pyogenes, supra) over 10 contiguous amino acids in the RuvC nuclease domain of the endonuclease. The endonuclease may comprise up to 70, 75, 80, 85, 90, 95, 97, 99, or 100% identity to a wild-type endonuclease (e.g., Cas9 from S. pyogenes, supra) over 10 contiguous amino acids in the RuvC nuclease domain of the endonuclease.
[0062] The endonuclease may include a modified form of the wild-type exemplary endonuclease. The modified form of the wild-type exemplary endonuclease may include a mutation that reduces the nucleic acid cleavage activity of the endonuclease. The modified form of the wild-type exemplary endonuclease may have less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1% of the nucleic acid cleavage activity of the wild-type exemplary endonuclease (e.g., Cas9 from S. pyogenes, supra). The modified form of the endonuclease may not have substantial nucleic acid cleavage activity. When the endonuclease is a modified form that does not have substantial nucleic acid cleavage activity, it is referred to herein as "without enzymatic activity".
[0063] Contemplated mutations may include substitutions, additions, and deletions, or any combination thereof. The mutation converts the mutated amino acid to alanine. The mutation converts the mutated amino acid to another amino acid (e.g., glycine, serine, threonine, cysteine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, asparagine, glutamine, histidine, lysine, or arginine). The mutation converts the mutated amino acid to a non-natural amino acid (e.g., selenomethionine). The mutation converts the mutated amino acid to an amino acid mimic (e.g., a phosphomimic). The mutation may be a conservative mutation. For example, the mutation converts the mutated amino acid to an amino acid similar in size, shape, charge, polarity, conformation, and / or rotamer to the mutated amino acid (e.g., a cysteine / serine mutation, a lysine / asparagine mutation, a histidine / phenylalanine mutation). The mutations may cause a shift in the reading frame and / or the generation of a premature stop codon. The mutations may cause changes to the regulatory regions of a gene or locus that affect the expression of one or more genes.
[0064] Guide RNA The present disclosure provides a guide RNA (gRNA) that can direct the activity of an associated endonuclease to a specific target site within a polynucleotide. The guide RNA can include a target nucleic acid sequence of interest and at least one spacer sequence that hybridizes to a CRISPR repeat sequence. In a type II CRISPR system, the gRNA also includes a second RNA called a tracrRNA sequence. In a type II CRISPR guide RNA (gRNA), the CRISPR repeat sequence and the tracrRNA sequence hybridize to each other to form a duplex. In a type V CRISPR system, the gRNA includes a crRNA that forms a duplex. In some embodiments, the gRNA can bind to an endonuclease, such that the gRNA and the endonuclease form a complex. The gRNA can provide target specificity to the complex due to association with the endonuclease. Thus, the genome targeting nucleic acid can direct the activity of an endonuclease.
[0065] Exemplary guide RNAs include spacer sequences containing 15-200 nucleotides, and the gRNAs target genomic locations based on the GRCh38 human genome assembly. As will be appreciated by those skilled in the art, each gRNA can be designed to include a spacer sequence complementary to its genomic target site or region. See Jinek et al., Science, 2012, 337, 816-821 and Deltcheva et al., Nature, 2011, 471, 602-607.
[0066] The gRNA can be a dual molecule guide RNA. The gRNA can be a single molecule guide RNA.
[0067] The dual molecule guide RNA may comprise two strands of RNA. The first strand comprises, in the 5' to 3' direction, an optional spacer extension sequence, a spacer sequence and a minimal CRISPR repeat sequence. The second strand may comprise a minimal tracrRNA sequence (complementary to the minimal CRISPR repeat sequence), a 3'tracrRNA sequence and an optional tracrRNA extension sequence.
[0068] A single-molecule guide RNA (sgRNA) may include, from 5' to 3', an optional spacer extension sequence, a spacer sequence, a minimal CRISPR repeat sequence, a single-molecule guide linker, a minimal tracrRNA sequence, a 3' tracrRNA sequence, and an optional tracrRNA extension sequence. The optional tracrRNA extension may include elements that contribute additional functionality (e.g., stability) to the guide RNA. The single-molecule guide linker may link the minimal CRISPR repeat and the minimal tracrRNA sequence to form a hairpin structure. The optional tracrRNA extension may include one or more hairpins.
[0069] In some embodiments, the sgRNA comprises a spacer sequence of 20 nucleotides at the 5' end of the sgRNA sequence. In some embodiments, the sgRNA comprises a spacer sequence of less than 20 nucleotides at the 5' end of the sgRNA sequence. In some embodiments, the sgRNA comprises a spacer sequence longer than 20 nucleotides at the 5' end of the sgRNA sequence. In some embodiments, the sgRNA comprises a variable length spacer sequence having 17-30 nucleotides at the 5' end of the sgRNA sequence. In some embodiments, the sgRNA comprises a spacer extension sequence having a length of more than 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, or 200 nucleotides. In some embodiments, the sgRNA comprises a spacer extension sequence having a length of less than 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 100 nucleotides.
[0070] In some embodiments, the sgRNA comprises a spacer extension sequence that comprises another moiety (e.g., a stability control sequence, an endoribonuclease binding sequence, or a ribozyme). The moiety can reduce or increase the stability of the nucleic acid targeting nucleic acid. The moiety can be a transcription terminator segment (i.e., a transcription termination sequence). The moiety can function in eukaryotic cells. The moiety can function in prokaryotic cells. The moiety can function in both eukaryotic and prokaryotic cells. Non-limiting examples of suitable moieties include a 5' cap (e.g., a 7-methylguanylate cap (m7 G)), a riboswitch sequence (e.g., allowing for modulation of stability and / or modulation of accessibility by proteins and protein complexes), a sequence that forms a dsRNA duplex (i.e., a hairpin), a sequence that targets the RNA to a subcellular location (e.g., the nucleus, mitochondria, chloroplast, etc.), a modification or sequence that provides for tracking (e.g., direct conjugation to a fluorescent molecule, conjugation to a moiety that facilitates fluorescent detection, a sequence that allows for fluorescent detection, etc.), and / or a modification or sequence that provides a binding site for a protein (e.g., a protein that acts on DNA, including a transcriptional activator, a transcriptional repressor, a DNA methyltransferase, a DNA demethylase, a histone acetyltransferase, a histone deacetylase, etc.).
[0071] In some embodiments, the sgRNA comprises a spacer sequence that hybridizes to a sequence in the target polynucleotide. The spacer of the gRNA can interact with the target polynucleotide in a sequence-specific manner through hybridization (i.e., base pairing). The nucleotide sequence of the spacer may vary depending on the sequence of the target nucleic acid of interest.
[0072] In the CRISPR-endonuclease system, the spacer sequence can be designed to hybridize to the target polynucleotide located 5' of the PAM of the endonuclease used in the system. The spacer can be a perfect match to the target sequence or can have a mismatch. Each endonuclease, such as the Cas9 nuclease, has a specific PAM sequence that it recognizes in the target DNA. For example, S. pyogenes Cas9 recognizes a PAM that includes the sequence 5'-NRG-3' (wherein R includes either A or G, N is any nucleotide, and N is immediately 3' of the target nucleic acid sequence targeted by the spacer sequence).
[0073] The target polynucleotide sequence may comprise 20 nucleotides. The target polynucleotide may comprise less than 20 nucleotides. The target polynucleotide may comprise more than 20 nucleotides. The target polynucleotide may comprise at least 5, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30 or more nucleotides. The target polynucleotide may comprise up to 5, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30 or more nucleotides. The target polynucleotide sequence may comprise 20 bases immediately 5' of the first nucleotide of the PAM.
[0074] The spacer sequence that hybridizes to the target polynucleotide may have a length of at least about 6 nucleotides (nt). The spacer sequence may be at least about 6 nt, at least about 10 nt, at least about 15 nt, at least about 18 nt, at least about 19 nt, at least about 20 nt, at least about 25 nt, at least about 30 nt, at least about 35 nt, or at least about 40 nt, from about 6 nt to about 80 nt, from about 6 nt to about 50 nt, from about 6 nt to about 45 nt, from about 6 nt to about 40 nt, from about 6 nt to about 35 nt, from about 6 nt to about 30 nt, from about 6 nt to about 25 nt, from about 6 nt to about 20 nt, from about 6 nt to about 19 nt, from about 10 nt to about 50 nt, from about 10 nt to about 45 nt, from about It may be 10nt to about 40nt, about 10nt to about 35nt, about 10nt to about 30nt, about 10nt to about 25nt, about 10nt to about 20nt, about 10nt to about 19nt, about 19nt to about 25nt, about 19nt to about 30nt, about 19nt to about 35nt, about 19nt to about 40nt, about 19nt to about 45nt, about 19nt to about 50nt, about 19nt to about 60nt, about 20nt to about 25nt, about 20nt to about 30nt, about 20nt to about 35nt, about 20nt to about 40nt, about 20nt to about 45nt, about 20nt to about 50nt, or about 20nt to about 60nt. In some examples, the spacer sequence may include 20 nucleotides. In some examples, the spacer may include 19 nucleotides. In some examples, the spacer may include 18 nucleotides. In some examples, the spacer may comprise 22 nucleotides.
[0075] In some instances, the percent complementarity between the spacer sequence and the target nucleic acid is at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98%, at least about 99%, or 100%. In some instances, the percent complementarity between the spacer sequence and the target nucleic acid is up to about 30%, up to about 40%, up to about 50%, up to about 60%, up to about 65%, up to about 70%, up to about 75%, up to about 80%, up to about 85%, up to about 90%, up to about 95%, up to about 97%, up to about 98%, up to about 99%, or 100%. In some instances, the percent complementarity between the spacer sequence and the target nucleic acid is 100% over 6 contiguous 5'-most nucleotides of the target sequence of the complementary strand of the target nucleic acid. The percent complementarity between the spacer sequence and the target nucleic acid can be at least 60% over about 20 contiguous nucleotides. The length of the spacer sequence and the target nucleic acid can differ by 1-6 nucleotides, which can be considered a bulge or bulges.
[0076] The tracrRNA sequence may comprise nucleotides that hybridize to the minimal CRISPR repeat sequence in a cell. The minimal tracrRNA sequence and the minimal CRISPR repeat sequence may form a duplex, i.e., a base-paired double-stranded structure. Together, the minimal tracrRNA sequence and the minimal CRISPR repeat may bind to an RNA-guided endonuclease. At least a portion of the minimal tracrRNA sequence may hybridize to the minimal CRISPR repeat sequence. The minimal tracrRNA sequence may be at least about 30%, about 40%, about 50%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or 100% complementary to the minimal CRISPR repeat sequence.
[0077] The minimal tracrRNA sequence may have a length of about 7 nucleotides to about 100 nucleotides. For example, the minimal tracrRNA sequence may be about 7 nucleotides (nt) to about 50 nt, about 7 nt to about 40 nt, about 7 nt to about 30 nt, about 7 nt to about 25 nt, about 7 nt to about 20 nt, about 7 nt to about 15 nt, about 8 nt to about 40 nt, about 8 nt to about 30 nt, about 8 nt to about 25 nt, about 8 nt to about 20 nt, about 8 nt to about 15 nt, about 15 nt to about 100 nt, about 15 nt to about 80 nt, about 15 nt to about 50 nt, about 15 nt to about 40 nt, about 15 nt to about 30 nt, or about 15 nt to about 25 nt long. The minimal tracrRNA sequence may be about 9 nucleotides long. The minimal tracrRNA sequence may be about 12 nucleotides long. The minimal tracrRNA may consist of tracrRNA nt 23-48 as described in Jinek et al., supra.
[0078] The minimal tracrRNA sequence may be at least about 60% identical to a reference minimal tracrRNA (e.g., wild-type, S. pyogenes derived tracrRNA) sequence over a stretch of at least 6, 7, or 8 contiguous nucleotides. For example, the minimal tracrRNA sequence may be at least about 65% identical, about 70% identical, about 75% identical, about 80% identical, about 85% identical, about 90% identical, about 95% identical, about 98% identical, about 99% identical, or 100% identical to a reference minimal tracrRNA sequence over a stretch of at least 6, 7, or 8 contiguous nucleotides.
[0079] The duplex between the minimal CRISPR RNA and the minimal tracrRNA may comprise a double helix. The duplex between the minimal CRISPR RNA and the minimal tracrRNA may comprise at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more nucleotides. The duplex between the minimal CRISPR RNA and the minimal tracrRNA may comprise up to about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more nucleotides.
[0080] A duplex may contain mismatches (i.e., the two strands of the duplex are not 100% complementary). A duplex may contain at least about 1, 2, 3, 4, or 5 mismatches. A duplex may contain up to about 1, 2, 3, 4, or 5 mismatches. A duplex may contain no more than 2 mismatches.
[0081] In some embodiments, the tracrRNA can be a 3'tracrRNA. In some embodiments, the 3'tracrRNA sequence can include a sequence having at least about 30%, about 40%, about 50%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or 100% sequence identity to a reference tracrRNA sequence (e.g., a tracrRNA from S. pyogenes).
[0082] In some embodiments, the gRNA may comprise a tracrRNA extension sequence. The tracrRNA extension sequence may have a length of about 1 nucleotide to about 400 nucleotides. The tracrRNA extension sequence may have a length of 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, or more than 200 nucleotides. The tracrRNA extension sequence may have a length of about 20 to about 5000 or more nucleotides. The tracrRNA extension sequence may have a length of less than 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or less than 100 nucleotides. The tracrRNA extension sequence may comprise a length of less than 10 nucleotides. The tracrRNA extension sequence may be 10 to 30 nucleotides in length. The tracrRNA extension sequence can be 30-70 nucleotides in length.
[0083] The tracrRNA extension sequence may include a functional portion (e.g., a stability control sequence, a ribozyme, an endoribonuclease binding sequence). The functional portion may include a transcription terminator segment (i.e., a transcription termination sequence). The functional portion may have a total length of about 10 nucleotides (nt) to about 100 nucleotides, about 10 nt to about 20 nt, about 20 nt to about 30 nt, about 30 nt to about 40 nt, about 40 nt to about 50 nt, about 50 nt to about 60 nt, about 60 nt to about 70 nt, about 70 nt to about 80 nt, about 80 nt to about 90 nt, or about 90 nt to about 100 nt, about 15 nt to about 80 nt, about 15 nt to about 50 nt, about 15 nt to about 40 nt, about 15 nt to about 30 nt, or about 15 nt to about 25 nt.
[0084] In some embodiments, the sgRNA may include a linker sequence having a length of about 3 nucleotides to about 100 nucleotides. In Jinek et al., supra, for example, a simple four nucleotide "tetraloop" (-GAAA-) was used (Jinek et al., Science, 2012, 337(6096):816-821). Exemplary linkers have a length of about 3 nucleotides (nt) to about 90 nt, about 3 nt to about 80 nt, about 3 nt to about 70 nt, about 3 nt to about 60 nt, about 3 nt to about 50 nt, about 3 nt to about 40 nt, about 3 nt to about 30 nt, about 3 nt to about 20 nt, about 3 nt to about 10 nt. For example, the linker may have a length of about 3 nt to about 5 nt, about 5 nt to about 10 nt, about 10 nt to about 15 nt, about 15 nt to about 20 nt, about 20 nt to about 25 nt, about 25 nt to about 30 nt, about 30 nt to about 35 nt, about 35 nt to about 40 nt, about 40 nt to about 50 nt, about 50 nt to about 60 nt, about 60 nt to about 70 nt, about 70 nt to about 80 nt, about 80 nt to about 90 nt, or about 90 nt to about 100 nt. The linker of the single molecule guide nucleic acid may be 4 to 40 nucleotides. The linker can be at least about 100, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, or 7000 or more nucleotides. The linker can be up to about 100, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, or 7000 or more nucleotides.
[0085] The linker may comprise any of a variety of sequences, but in some instances, the linker will not comprise sequences with extensive regions of homology with other parts of the guide RNA that may cause intramolecular binding that would interfere with other functional regions of the guide. In Jinek et al., supra, a simple four-nucleotide sequence -GAAA- was used (Jinek et al., Science, 2012, 337(6096):816-821), but numerous other sequences, including longer sequences, may be used as well.
[0086] The linker sequence may comprise a functional moiety. For example, the linker sequence may comprise one or more features including an aptamer, a ribozyme, a protein-interacting hairpin, a protein binding site, a CRISPR array, an intron, or an exon. The linker sequence may comprise at least about 1, 2, 3, 4, or 5 or more functional moieties. In some examples, the linker sequence may comprise up to about 1, 2, 3, 4, or 5 or more functional moieties.
[0087] In some embodiments, the sgRNA does not include uracil, e.g., at the 3' end of the sgRNA sequence. In some embodiments, the sgRNA includes one or more uracils, e.g., at the 3' end of the sgRNA sequence. In some embodiments, the sgRNA includes 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 uracils (U) at the 3' end of the sgRNA sequence.
[0088] The sgRNA may be chemically modified. In some embodiments, the chemically modified gRNA is a gRNA that includes at least one nucleotide with a chemical modification, such as a 2'-O-methyl sugar modification. In some embodiments, the chemically modified gRNA includes a modified nucleic acid backbone. In some embodiments, the chemically modified gRNA includes 2'-O-methyl-phosphorothioate residues. In some embodiments, the chemical modification enhances stability, reduces the likelihood or extent of an innate immune response, and / or enhances other attributes, as described in the art.
[0089] In some embodiments, modified gRNAs may include modified backbones, such as phosphorothioates, phosphotriesters, morpholinos, methylphosphonates, short chain alkyl or cycloalkyl intersugar linkages, or short chain heteroatom or heterocyclic intersugar linkages.
[0090] Morpholino compounds are described in Braasch and David Corey, Biochemistry, 2002, 41(14):4503-4510; Genesis, 2001, Volume 30, Issue 3; Heasman, Dev. Biol., 2002, 243:209-214; Nasevicius et al., Nat. Genet., 2000, 26:216-220; Lacerra et al., Proc. Natl. Acad. Sci., 2000, 97:9591-9596; and U.S. Patent No. 5,034,506, issued July 23, 1991.
[0091] Cyclohexenyl nucleic acid oligonucleotide mimetics are described in Wang et al., J. Am. Chem. Soc., 2000, 122:8595-8602.
[0092] In some embodiments, the modified gRNA may include one or more substituted sugar moieties at the 2' position, such as one of the following: OH, SH, SCH3, F, OCN, OCH3, OCHO(CH2)nCH3, O(CH2)nNH2, or O(CH2)nCH3 (n is 1 to about 10); C1 to C10 lower alkyl, alkoxyalkoxy, substituted lower alkyl, alkaryl, or aralkyl; Cl; Br; CN; CF3; OCF3; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; SOCH3; SO2CH3; ONO2; NO2; N3; NH2; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; RNA cleaving group; reporter group; interfering agent; 2'-O-(2-methoxyethyl); 2'-methoxy (2'-O-CH3); 2'-propoxy (2'-OCH2CH2CH3); and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the gRNA, particularly at the 3' position of the sugar on the 3'-terminal nucleotide and the 5' position of the 5'-terminal nucleotide. In some instances, both the sugar and the internucleoside linkage of the nucleotide units, i.e., the backbone, may be replaced with novel groups.
[0093] Guide RNAs may also additionally or alternatively include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include adenine (A), guanine (G), thymine (T), cytosine (C), and uracil (U). Modified nucleobases include nucleobases that are found only rarely or occasionally in natural nucleic acids, such as hypoxanthine, 6-methyladenine, 5-Me pyrimidines, particularly 5-methylcytosine (also called 5-methyl-2'-deoxycytosine and often referred to in the art as 5-Me-C), 5-hydroxymethylcytosine (HMC), glycosyl MHC and gentobiosyl HMC, as well as synthetic nucleobases such as 2-aminoadenine, 2-(methylamino)adenine, 2-(imidazolylalkyl)adenine, 2-(aminoalkylamino)adenine or other hetero-substituted alkyl adenines, 2-thiouracil, 2-thiothymine, 5-bromouracil, 5-hydroxymethyluracil, 8-azaguanine, 7-deazaguanine, N6(6-aminohexyl)adenine, and 2,6-diaminopurine. Kornberg, A., DNA Replication, WH Freeman & Co., San Francisco, pp75-77, 1980; Gebeyehu et al., Nucl.Acids Res.1997,15:4513. "Universal" bases known in the art, such as inosine, may also be included. 5-Me-C substitutions have been shown to increase the stability of nucleic acid duplexes by 0.6-1.2°C (Sanghvi, YS, in Crooke, ST and Lebleu, B., eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp.276-278), and are an embodiment of base substitutions.
[0094] Modified nucleobases include 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyluracil and cytosine, 6-azouracil, cytosine and thymine, 5-uracil (pseudo-uracil), 4-thiouracil, 5-thiocytosine, 5 ... The bases may include other synthetic and natural nucleobases such as uracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo, particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracil and cytosines, 7-methylquanine and adenine, 8-azaguanine and adenine, 7-deazaguanine and adenine, and 3-deazaguanine and adenine.
[0095] Complex of genome-targeting nucleic acid and endonuclease The gRNA interacts with an endonuclease (e.g., an RNA-guided nuclease such as Cas9), thereby forming a complex. The gRNA guides the endonuclease to a target polynucleotide.
[0096] The endonuclease and gRNA may each be administered separately to a cell or subject. In some embodiments, the endonuclease may be precomplexed with one or more guide RNAs, or one or more crRNAs combined with tracrRNA. The precomplexed material may then be administered to a cell or subject. Such precomplexed material is known as a ribonucleoprotein particle (RNP). The endonuclease in the RNP may be, for example, a Cas9 endonuclease or a Cpf1 endonuclease. The endonuclease may be flanked at the N-terminus, C-terminus, or both the N-terminus and C-terminus by one or more nuclear localization signals (NLS). For example, the Cas9 endonuclease may be flanked by two NLSs, one NLS located at the N-terminus and a second NLS located at the C-terminus. The NLS may be any NLS known in the art, such as the SV40 NLS. The weight ratio of genome-targeting nucleic acid to endonuclease in the RNP may be 1:1. For example, the weight ratio of sgRNA to Cas9 endonuclease in the RNP can be 1:1.
[0097] Nucleic acid coding system components The present disclosure provides nucleic acids comprising nucleotide sequences encoding the genome-targeting nucleic acids of the present disclosure, the endonucleases of the present disclosure, and / or any nucleic acid or proteinaceous molecules necessary to carry out aspects of the methods of the present disclosure. The encoding nucleic acid can be RNA, DNA, or a combination thereof.
[0098] The nucleic acids encoding the genome-targeting nucleic acids of the present disclosure, the endonucleases of the present disclosure, and / or any nucleic acid or proteinaceous molecules necessary to carry out aspects of the methods of the present disclosure can be comprised in a vector (e.g., a recombinant expression vector).
[0099] The term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid," which refers to a circular double-stranded DNA loop into which additional nucleic acid segments can be ligated. Another type of vector is a viral vector, in which additional nucleic acid segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of the host cell upon introduction into the host cell, and are thereby replicated along with the host genome.
[0100] In some instances, vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" or, more simply, "expression vectors," which serve the same function.
[0101] The term "operably linked" means that the nucleotide sequence of interest is linked to a regulatory sequence in a manner that allows expression of the nucleotide sequence. The term "regulatory sequence" is intended to include, for example, promoters, enhancers, and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are well known in the art and are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology, 1990, 185, Academic Press, San Diego, CA. Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cells and those that direct expression of a nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be recognized by those skilled in the art that the design of the expression vector may depend on factors such as the choice of the target cell, the level of expression desired, and the like.
[0102] Contemplated expression vectors include, but are not limited to, viral vectors based on vaccinia virus, poliovirus, adenovirus, adeno-associated virus, SV40, herpes simplex virus, human immunodeficiency virus, retrovirus (e.g., vectors derived from murine leukemia virus, spleen necrosis virus, and retroviruses such as Rous sarcoma virus, Harvey sarcoma virus, avian leukosis virus, lentivirus, human immunodeficiency virus, myeloproliferative sarcoma virus, and mammary tumor virus) and other recombinant vectors. Other vectors contemplated for eukaryotic target cells include, but are not limited to, vectors pXT1, pSG5, pSVK3, pBPV, pMSG, and pSVLSV40 (Pharmacia). Other vectors may be used as long as they are compatible with the host cell.
[0103] In some examples, the vector may include one or more transcription and / or translation control elements. Depending on the host / vector system utilized, any of a number of suitable transcription and translation control elements, including constitutive and inducible promoters, transcription enhancer elements, transcription terminators, etc., may be used in the expression vector. The vector may be a self-inactivating vector that inactivates any of the viral sequences or components of the CRISPR mechanism or other elements.
[0104] Non-limiting examples of suitable eukaryotic promoters (i.e., promoters that function in eukaryotic cells) include those derived from the cytomegalovirus (CMV) immediate early, herpes simplex virus (HSV) thymidine kinase, early and late SV40, long terminal repeats (LTRs) from retroviruses, human elongation factor-1 promoter (EF1), chicken beta-actin promoter (CBA), ubiquitin C promoter (UBC), a hybrid construct comprising a cytomegalovirus enhancer fused to the chicken beta-actin promoter (CAG), a hybrid construct comprising a cytomegalovirus enhancer fused to the promoter, first exon, and first intron of the chicken beta-actin gene (CAG or CAGGS), a mouse stem cell virus promoter (MSCV), a phosphoglycerate kinase-1 locus promoter (PGK), and a mouse metallothionein-I promoter.
[0105] The promoter may be an inducible promoter (e.g., a heat shock promoter, a tetracycline-regulated promoter, a steroid-regulated promoter, a metal-regulated promoter, an estrogen receptor-regulated promoter, etc.). The promoter may be a constitutive promoter (e.g., a CMV promoter, a UBC promoter, a CAG promoter). In some cases, the promoter may be a spatially constrained promoter and / or a temporally constrained promoter (e.g., a tissue-specific promoter, a cell type-specific promoter, etc.).
[0106] Introduction of the complexes, polypeptides, and nucleic acids of the present disclosure into cells may be by viral or bacteriophage infection, transfection, conjugation, protoplast fusion, lipofection, electroporation, nucleofection, calcium phosphate precipitation, polyethyleneimine (PEI)-mediated transfection, DEAE-dextran mediated transfection, liposome-mediated transfection, particle gun technology, calcium phosphate precipitation, direct microinjection, nanoparticle-mediated nucleic acid delivery, and the like.
[0107] III. Strategies to evade immune responses and increase survival Described herein are strategies that allow genetically modified cells, i.e., universal donor cells, to avoid immune responses and / or increase their survival time or survival rate after engraftment into a subject. In some embodiments, these strategies allow the universal donor cells to avoid immune responses and / or survive with a higher success rate than unmodified cells. In some embodiments, the genetically modified cells include the introduction of at least one genetic modification in or near at least one gene that reduces expression of one or more MHC-I and MHC-II human leukocyte antigens relative to unmodified cells; at least one genetic modification that increases expression of at least one polynucleotide encoding an immune tolerogenic factor relative to unmodified cells; and / or at least one genetic modification that modifies expression of at least one gene encoding a survival factor relative to unmodified cells. In some embodiments, the genetically modified cells include the introduction of at least one genetic modification in or near at least one gene that reduces expression of one or more MHC-I and MHC-II human leukocyte antigens relative to an unmodified cell; at least one genetic modification that increases expression of at least one polynucleotide encoding a tolerogenic factor relative to an unmodified cell; and at least one genetic modification that modifies expression of at least one gene encoding a survival factor relative to an unmodified cell. In other embodiments, the genetically modified cells include at least one deletion or insertion-deletion mutation in or near at least one gene that modifies expression of one or more MHC-I and MHC-II human leukocyte antigens relative to an unmodified cell; and at least one insertion of a polynucleotide encoding at least one tolerogenic factor at a site that partially overlaps, completely overlaps, or is contained within a site of deletion of a gene that modifies expression of one or more MHC-I and MHC-II HLA. In yet other embodiments, the genetically modified cells include at least one genetic modification that modifies expression of at least one gene encoding a survival factor relative to an unmodified cell.
[0108] Genes encoding the major histocompatibility complex (MHC) are located on human Chr.6p21. The resulting proteins encoded by MHC genes are a series of surface proteins that are essential for donor compatibility during cell transplantation. MHC genes are classified as MHC class I (MHC-I) and MHC class II (MHC-II). MHC-I genes (HLA-A, HLA-B, and HLA-C) are expressed in almost all tissue types and present "non-self" antigen-processed peptides to CD8+ T cells, thereby promoting their activation into cytolytic CD8+ T cells. Transplanted or engrafted cells expressing "non-self" MHC-I molecules will trigger a strong cellular immune response directed against these cells, ultimately resulting in their elimination by activated cytolytic CD8+ T cells. MHC-I proteins are essentially associated with beta-2-microglobulin (B2M) in the endoplasmic reticulum, which is essential for the formation of functional MHC-I molecules on the cell surface. In addition, there are three non-classical MHC-1b molecules (HLA-E, HLA-F, and HLA-G) that have immune-regulatory functions. MHC-II biomolecules include HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, and HLA-DR. Due to their key functions in the immune response, MHC-I and MHC-II biomolecules contribute to immune rejection after cell engraftment of non-host cells, for example, cell engraftment for regenerative medicine purposes.
[0109] MHC-I cell surface molecules are composed of MHC-encoded heavy chains (HLA-A, HLA-B, or HLA-C) and the invariant subunit beta-2-microglobulin (B2M). Thus, reducing the concentration of B2M within a cell provides an effective method of reducing cell surface expression of MHC-I cell surface molecules.
[0110] In some embodiments, the cells comprise genetic modifications of one or more MHC-I or MHC-II genes. In some embodiments, the cells comprise genetic modifications of one or more polynucleotide sequences that regulate expression of MHC-I and / or MHC-II. In some embodiments, the genetic modifications of the present disclosure are performed using any gene editing method, including but not limited to those described herein.
[0111] In some embodiments, reducing the expression of one or more MHC-I and MHC-II human leukocyte antigens relative to unmodified cells is achieved by targeting, for example, for gene deletion and / or insertion of at least one base pair directly in the MHC-I and / or MHC-II genes. In some embodiments, reducing the expression of one or more MHC-I and MHC-II human leukocyte antigens relative to unmodified cells is achieved by targeting, for example, for gene deletion, the CIITA gene. In some embodiments, reducing the expression of one or more MHC-I and MHC-II human leukocyte antigens relative to unmodified cells is achieved by targeting, for example, for gene deletion, at least one transcriptional regulator of MHC-I or MHC-II. In some embodiments, the transcriptional regulator of MHC-I or MHC-II is the NLRC5 or CIITA gene. In some embodiments, the transcriptional regulator of MHC-I or MHC-II is the RFX5, RFXAP, RFXANK, NFY-A, NFY-B, NFY-C, IRF-1, and / or TAP1 gene.
[0112] In some embodiments, the genome of the cell has been modified to delete all or a portion of the HLA-A, HLA-B, and / or HLA-C genes. In some embodiments, the genome of the cell has been modified to delete all or a portion of the promoter region of the HLA-A, HLA-B, and / or HLA-C genes. In some embodiments, the genome of the cell has been modified to delete all or a portion of the gene encoding a transcriptional regulator of MHC-I or MHC-II. In some embodiments, the genome of the cell has been modified to delete all or a portion of the promoter region of the gene encoding a transcriptional regulator of MHC-I or MHC-II.
[0113] In some embodiments, the genome of the cell is modified to reduce expression of beta-2-microglobulin (B2M). B2M is a non-polymorphic gene that encodes a shared protein subunit required for surface expression of all polymorphic MHC class I heavy chains. HLA-I proteins directly associate with B2M in the endoplasmic reticulum, which is essential for forming functional cell surface expressed HLA-I molecules. In some embodiments, the gRNA targets a site in the B2M gene that includes the 5'GCTACTCTCTCTTTCTGGCC3' sequence (SEQ ID NO:1). In some embodiments, the gRNA targets a site in the B2M gene that includes the 5'GGCCGAGATGTCTCGCTCCG3' sequence (SEQ ID NO:2). In some embodiments, the gRNA targets a site in the B2M gene that includes the 5'CGCGAGCACAGCTAAGGCCA3' sequence (SEQ ID NO:3). In alternative embodiments, the gRNA targets a site within the B2M gene comprising any of the following sequences: 5'-TATAAGTGGAGGCGTCGCGC-3' (SEQ ID NO: 35), 5'-GAGTAGCGCGAGCACAGCTA-3' (SEQ ID NO: 36), 5'-ACTGGACGCGTCGCGCTGGC-3' (SEQ ID NO: 37), 5'-AAGTGGAGGCGTCGCGCTGG-3' (SEQ ID NO: 38), 5-GGCCACGGAGCGAGACATCT-3' (SEQ ID NO: 39), 5'-GCCCGAATGCTGTCAGCTTC-3' (SEQ ID NO: 40), 5'-CTCGCGCTACTCTCTCTTTC-3' (SEQ ID NO: 41), 5'-TCCTGAAGCTGACAGCATTC-3' (SEQ ID NO: 42), 5'-TTCCTGAAGCTGACAGCATT-3' (SEQ ID NO: 43), or 5'-ACTCTCTCTTTCTGGCCTGG-3' (SEQ ID NO: 44). In some embodiments, the gRNA comprises any one of the polynucleotide sequences of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, or SEQ ID NO:44. The gRNA / CRISPR nuclease complex targets and cleaves the target site in the B2M locus.Repair of the double-stranded break by NHEJ can result in a deletion of at least one nucleotide and / or an insertion of at least one nucleotide, thereby disrupting or eliminating expression of B2M. Alternatively, the B2M locus can be targeted by at least two CRISPR systems, each containing a different gRNA, such that cleavage at two sites in the B2M locus results in the deletion of the sequence between the two cleavage sites, thereby eliminating expression of B2M.
[0114] In some embodiments, the genome of the cells is modified to reduce expression of class II transactivator (CIITA). CIITA is a member of the LR or nucleotide binding domain (NBD) leucine-rich repeat (LRR) family of proteins that regulates MHC-II transcription by associating with the MHC enhanceosome. Expression of CIITA is induced in B cells and dendritic cells depending on the developmental stage, and is inducible by IFN-γ in most cell types.
[0115] In some embodiments, the genome of the cells is modified to reduce the expression of NLR family CARD domain containing 5 (NLRC5). NLRC5 is a critical regulator of MHC-I mediated immune responses, and like CIITA, NLRC5 is highly inducible by IFN-γ and can translocate into the nucleus. NLRC5 activates the promoter of MHC-I genes and induces the transcription of related genes involved in MHC-I and MHC-I antigen presentation.
[0116] In some embodiments, tolerogenic factors can be inserted or reinserted into the genetically modified cells to create immune privileged universal donor cells. In some embodiments, the universal donor cells disclosed herein are further modified to express one or more tolerogenic factors. Exemplary tolerogenic factors include, but are not limited to, one or more of HLA-C, HLA-E, HLA-F, HLA-G, PD-L1, CTLA-4-Ig, CD47, CI-inhibitor, and IL-35. In some embodiments, the genetic modification, e.g., insertion, of at least one polynucleotide encoding at least one tolerogenic factor allows the universal donor cells to inhibit or avoid immune rejection at least 1.05-fold, at least 1.1-fold, at least 1.25-fold, at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, or at least 50-fold higher than unmodified cells after engraftment. In some embodiments, insertion of a polynucleotide encoding HLA-E, HLA-G, CTLA-4, CD47, and / or PD-L1 enables the universal donor cells to inhibit or avoid immune rejection following transplantation or engraftment into a host subject.
[0117] A polynucleotide encoding a tolerogenic factor generally comprises left and right homology arms flanking the sequence encoding the tolerogenic factor. The homology arms have substantial sequence homology with genomic DNA at or near the targeted insertion site. For example, the left homology arm can be a nucleotide sequence homologous to a region located to the left or upstream of the target site or cleavage site, and the right homology arm can be a nucleotide sequence homologous to a region located to the right or downstream of the target site or cleavage site. The proximal end of each homology arm can be homologous to a genomic DNA sequence adjacent to the cleavage site. Alternatively, the proximal end of each homology arm can be homologous to a genomic DNA sequence located up to about 10, 20, 30, 40, 50, 60, or 70 nucleobases away from the cleavage site. Thus, a polynucleotide encoding an immune tolerogenic factor can be inserted into a targeted locus within about 10, 20, 30, 40, 50, 60, or 70 base pairs of the cleavage site, and additional genomic DNA adjacent to the cleavage site (and not having homology to the homology arms) can be deleted. Homology arms can range in length from about 50 nucleotides to several thousand nucleotides. In some embodiments, homology arms can range in length from about 500 nucleotides to about 1000 nucleotides. Substantial sequence homology between the homology arms and the genomic DNA can be at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99%.
[0118] In some embodiments, the homology arms are used with B2M guides (e.g., gRNAs comprising the nucleotide sequence of SEQ ID NO: 1-3 or 35-44). In some embodiments, the homology arms are designed to be used with any B2M guide that will remove the start site of the B2M gene. In some embodiments, the B2M homology arms may comprise or essentially consist of a polynucleotide sequence of SEQ ID NO: 13 or 19, or a polynucleotide sequence having at least 85%, 90%, 95%, or 99% sequence identity to that of SEQ ID NO: 13 or 19. In some embodiments, the left B2M homology arm may comprise or essentially consist of SEQ ID NO: 13, or a polynucleotide sequence having at least 85%, 90%, 95%, or 99% sequence identity to that of SEQ ID NO: 13. In some embodiments, the right B2M homology arm may comprise or essentially consist of SEQ ID NO: 19, or a polynucleotide sequence having at least 85%, 90%, 95%, or 99% sequence identity to that of SEQ ID NO: 19.
[0119] At least one polynucleotide encoding at least one tolerogenic factor may be operably linked to an exogenous promoter. The exogenous promoter may be a constitutive, inducible, time-specific, tissue-specific, or cell-type specific promoter. In some embodiments, the exogenous promoter is a CMV, EFla, PGK, CAG, or UBC promoter.
[0120] In some embodiments, at least one polynucleotide encoding at least one tolerogenic factor is inserted into a safe harbor locus, e.g., the AAVS1 locus. In some embodiments, at least one polynucleotide encoding at least one tolerogenic factor is inserted into a site or region of genomic DNA that partially overlaps, completely overlaps, or is contained within (i.e., within or near) an MHC-I gene, an MHC-II gene, or a transcriptional regulator of MHC-I or MHC-II.
[0121] In some embodiments, the polynucleotide encoding PD-L1 is inserted at a site within or near the B2M locus. In some embodiments, the polynucleotide encoding PD-L1 is inserted at a site within or near the B2M locus that coincides with or follows a deletion of all or a portion of the B2M gene or promoter. The polynucleotide encoding PD-L1 is operably linked to an exogenous promoter. The exogenous promoter may be a CMV promoter.
[0122] In some embodiments, the polynucleotide encoding HLA-E is inserted at a site within or near the B2M locus. In some embodiments, the polynucleotide encoding HLA-E is inserted at a site within or near the B2M locus that coincides with or follows a deletion of all or a portion of the B2M gene or promoter. The polynucleotide encoding HLA-E is operably linked to an exogenous promoter. The exogenous promoter can be a CMV promoter.
[0123] In some embodiments, the polynucleotide encoding HLA-G is inserted at a site within or near the HLA-A, HLA-B, or HLA-C locus. In some embodiments, the polynucleotide encoding HLA-G is inserted at a site within or near the HLA-A, HLA-B, or HLA-C locus that coincides with or follows a deletion of the HLA-A, HLA-B, or HLA-C gene or promoter.
[0124] In some embodiments, the polynucleotide encoding CD47 is inserted at a site within or near the CIITA locus, hi some embodiments, the polynucleotide encoding CD47 is inserted at a site within or near the CIITA locus that coincides with or follows a deletion of the CIITA gene or promoter.
[0125] In some embodiments, a polynucleotide encoding HLA-G is inserted at a site within or near the HLA-A, HLA-B, or HLA-C locus that coincides with the insertion of a polynucleotide encoding CD47 at a site within or near the CIITA locus.
[0126] In some embodiments, the cells include an increased or decreased expression of one or more survival factors. In some embodiments, the cells include an insertion of one or more polynucleotide sequences encoding a survival factor. In some embodiments, the cells include a deletion of one of the additional survival factors. In some embodiments, the genetic modification of the present disclosure is performed using any gene editing method, including but not limited to those described herein. In some embodiments, the cells include an increased or decreased expression of at least one survival factor relative to unmodified cells. In some embodiments, the survival factor is a member or critical pathway involved in cell survival, such as hypoxia, reactive oxygen species, nutrient deprivation, and / or oxidative stress. In some embodiments, the genetic modification of at least one survival factor allows the universal donor cells to survive for a longer period than unmodified cells after engraftment, for example, at least 1.05-fold, at least 1.1-fold, at least 1.25-fold, at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, or at least 50-fold longer. In some embodiments, the survival factor is ZNF143, TXNIP, FOXO1, JNK, or MANF.
[0127] In some embodiments, the cells include an insertion of a polynucleotide encoding MANF, allowing the universal donor cells to survive at a higher rate after transplantation or engraftment into a host subject relative to unmodified cells. In some embodiments, the polynucleotide encoding MANF is inserted into a safe harbor locus. In some embodiments, the polynucleotide encoding MANF is inserted into a gene belonging to MHC-I, MHC-II, or a transcriptional regulator of MHC-I or MHC-II.
[0128] In some embodiments, the genome of the cell has been modified to delete all or a portion of the ZNF143, TXNIP, FOXO1, and / or JNK genes. In some embodiments, the genome of the cell has been modified to delete all or a portion of the promoter region of the ZNF143, TXNIP, FOXO1, and / or JNK genes.
[0129] In some embodiments, two or more survival factors are genetically modified in the cell.
[0130] In certain embodiments, cells that have no MHC-II expression and moderate expression of MHC-I are genetically modified to have no surface expression of MHC-I or MHC-II. In another embodiment, cells that have no surface expression of MHC-I / II are further edited to have expression of PD-L1, e.g., an insertion of a polynucleotide encoding PD-L1. In yet another embodiment, cells that have no surface expression of MHC-I / II are further edited to have expression of PD-L1, e.g., an insertion of a polynucleotide encoding PD-L1, and are also genetically modified to increase or decrease expression of at least one gene encoding a survival factor relative to the unmodified cell.
[0131] In some embodiments, the cells further comprise, for example, an increase or decrease in expression of one or more additional genes not necessarily related to either immune evasion or cell survival after engraftment, by genetic modification. In some embodiments, the cells further comprise an increase in expression of one or more safety switch proteins relative to unmodified cells. In some embodiments, the cells comprise an increase in expression of one or more additional genes encoding safety switch proteins. In some embodiments, the safety switch is also a suicide gene. In some embodiments, the safety switch is herpes simplex virus-1 thymidine kinase (HSV-tk) or inducible caspase-9. In some embodiments, a polynucleotide encoding at least one safety switch is inserted into the genome, for example, at a safe harbor locus. In some other embodiments, the one or more additional genes to be genetically modified encode one or more of the following: a safety switch protein integrated with the construct; a targeting modality; a receptor; a signaling molecule; a transcription factor; a pharmacologic active protein or peptide; a drug target candidate; and a protein that promotes its engraftment, transport, migration, viability, self-renewal, persistence, and / or survival.
[0132] One aspect of the present invention provides a method of making a genomically engineered universal donor cell (the universal donor cell comprises at least one targeted genomic modification at one or more selected sites in the genome), comprising: engineering a cell type as described herein by introducing one or more constructs into the cell that allow targeted modification at the selected site; introducing one or more double-strand breaks into the cell at the selected site using one or more endonucleases capable of selected site recognition; and culturing the edited cell to allow endogenous DNA repair to generate a targeted insertion or deletion at the selected site; thereby obtaining a genomically engineered universal donor cell. The universal donor cell made by this method will contain at least one functional targeted genomic modification, and the genomically engineered cells, if they are stem cells, can differentiate into progenitor cells or fully differentiated cells.
[0133] In some other embodiments, the genomically engineered universal donor cell comprises an introduction or increase in expression of at least one of HLA-E, HLA-G, CD47, or D-L1. In some embodiments, the genomically engineered universal donor cell is HLA class I and / or class II deficient. In some embodiments, the genomically engineered universal donor cell comprises B2M null or deficient B2M. In some embodiments, the genomically engineered universal donor cell comprises an integrated or non-integrated exogenous polynucleotide encoding one or more of HLA-E, HLA-G, and PD-L1. In some embodiments, the introduced expression is increased expression from either a non-expressed or deficient expressed gene contained in the cell. In some embodiments, the non-integrated exogenous polynucleotide is introduced using Sendai virus, AAV, episome, or plasmid. In some embodiments, the universal donor cell is B2M null with the introduction of expression of one or more of HLA-E, HLA-G, PD-L1, and increased or decreased expression of at least one safety switch protein. In another embodiment, the universal donor cell is HLA-A, HLA-B, and HLA-C null with the introduction of expression of one or more of HLA-E, HLA-G, PD-L1, and at least one safety switch protein. In some embodiments, the universal donor cell is B2M null with the introduction of expression of one or more of HLA-E, HLA-G, PD-L1, and increased or decreased expression of at least one survival factor, e.g., MANF. It is contemplated that the methods of making any of the genetically modified cells described herein are performed using at least any of the gene editing methods described herein.
[0134] IV.Cell type The cells, e.g., universal donor cells (and corresponding unmodified cells) as described herein, may belong to any possible class of cell type. In some embodiments, the cells, e.g., universal donor cells (and corresponding unmodified cells) may be mammalian cells. In some embodiments, the cells, e.g., universal donor cells (and corresponding unmodified cells) may be human cells. In some embodiments, the cells, e.g., universal donor cells (and corresponding unmodified cells) may be stem cells. In some embodiments, the cells, e.g., universal donor cells (and corresponding unmodified cells) may be pluripotent stem cells (PSCs). In some embodiments, the cells, e.g., universal donor cells (and corresponding unmodified cells) may be embryonic stem cells (ESCs), adult stem cells (ASCs), induced pluripotent stem cells (iPSCs), or hematopoietic stem and progenitor cells (HSPCs). In some embodiments, the cells, e.g., universal donor cells (and corresponding unmodified cells) may be differentiated cells. In some embodiments, the cells, e.g., universal donor cells (and the corresponding unmodified cells), may be somatic cells, e.g., immune system cells or contractile cells, e.g., skeletal muscle cells.
[0135] The cells described herein, for example, universal donor stem cells, can be differentiated into appropriate cell types to determine HLA expression and evaluate the immunogenicity of the universal stem cell line. In general, differentiation involves maintaining the cells of interest for a sufficient period of time and under conditions to differentiate the cells into the differentiated cells of interest. For example, the universal donor cells disclosed herein can be differentiated into mesenchymal progenitor cells (MPCs), low immunogenic cardiomyocytes, muscle progenitor cells, blast cells, endothelial cells (ECs), macrophages, stem cells, beta cells (e.g., pancreatic beta cells), pancreatic endoderm progenitor cells, pancreatic endocrine progenitor cells, or neural progenitor cells (NPCs).
[0136] Stem cells have the capacity to both proliferate and give rise to further progenitor cells, which have the capacity to generate a large number of mother cells that can give rise to differentiated or differentiable daughter cells. The daughter cells themselves can be induced to proliferate and generate progeny that subsequently differentiate into one or more mature cell types, but also retain one or more cells with the developmental potential of the parent. The term "stem cell" then refers to a cell that has the capacity or potential to differentiate into a more specific or differentiated phenotype under certain circumstances, and that retains the capacity to proliferate without substantial differentiation under certain circumstances. In one aspect, the term progenitor cell or stem cell refers to a general mother cell, whose progeny (progeny) often specialize in different directions by acquiring completely individual characteristics, as seen in differentiation, e.g., the gradual diversification of embryonic cells and tissues. Cell differentiation is a complex process that typically occurs through many cell divisions. Differentiated cells can be derived from pluripotent cells that are themselves derived from pluripotent cells, etc. Each of these pluripotent cells can be considered a stem cell, but the range of cell types each can give rise to can be highly variable. Some differentiated cells also have the ability to give rise to cells with higher developmental potential. Such ability may be natural or may be artificially induced upon treatment with various factors. In many biological examples, stem cells may also be "pluripotent" because they can generate progeny of two or more different cell types, although this is not necessary for "stemness".
[0137] A "differentiated cell" is a cell that is further along a developmental pathway than the cell to which it is being compared. Thus, stem cells can differentiate into lineage-restricted precursor cells (such as muscle cell precursors), which can differentiate into other types of precursor cells further along the pathway (such as muscle cell precursors), and then into end-stage differentiated cells, such as muscle cells, which may or may not retain the ability to play characteristic roles in certain tissue types and further proliferate.
[0138] embryonic stem cells The cells described herein may be embryonic stem cells (ESCs). ESCs are derived from the blastocysts of mammalian embryos and can differentiate into any cell type and proliferate rapidly. ESCs are also believed to have normal karyotypes, maintain high telomerase activity, and exhibit significant long-term proliferation potential, making these cells excellent candidates for use as universal donor cells.
[0139] adult stem cells The cells described herein may be adult stem cells (ASCs). ASCs are undifferentiated cells that can be found in mammals, e.g., humans. ASCs are defined by their ability to self-renew, e.g., pass through multiple rounds of cell duplication while maintaining an undifferentiated state, and to differentiate into multiple different cell types, e.g., glial cells. Adult stem cells are a broad class of stem cells that can include hematopoietic stem cells, mammary stem cells, intestinal stem cells, mesenchymal stem cells, endothelial stem cells, neural stem cells, olfactory adult stem cells, neural crest stem cells, and testicular cells.
[0140] induced pluripotent stem cells The cells described herein may be induced pluripotent stem cells (iPSCs). iPSCs can be generated directly from adult human cells by introducing genes encoding critical transcription factors involved in pluripotency, such as Oct4, Sox2, cMyc, and Klf4. iPSCs can be derived from the same subject to which the subsequent progenitor cells will be administered. That is, somatic cells can be obtained from a subject, reprogrammed into induced pluripotent stem cells, and then redifferentiated into progenitor cells (e.g., autologous cells) that will be administered to the subject. However, in the case of autologous cells, the risk of immune response and poor survival rate after engraftment remains.
[0141] Human hematopoietic stem and progenitor cells The cells described herein may be human hematopoietic stem and progenitor cells (hHSPCs). This stem cell lineage gives rise to all blood cell types, including erythroid (red blood cells or red blood cells (RBCs)), myeloid (monocytes and macrophages, neutrophils, basophils, eosinophils, megakaryocytes / platelets, and dendritic cells), and lymphoid (T cells, B cells, NK cells). Blood cells are produced by proliferation and differentiation of a very small number of multipotent hematopoietic stem cells (HSCs) that have the capacity to replenish themselves by self-renewal. During differentiation, the progeny of HSCs develop through various intermediate maturation stages, generating multipotent and lineage-committed progenitor cells before reaching maturity. The bone marrow (BM) is the primary site of hematopoietic development in humans, and under normal conditions, only a small number of hematopoietic stem and progenitor cells (HSPCs) can be found in the peripheral blood (PB). Treatment with cytokines, some myelosuppressive drugs used in cancer therapy, and compounds that disrupt interactions between hematopoietic and BM stromal cells can rapidly mobilize large numbers of stem and progenitor cells into the circulation.
[0142] Differentiation of cells into other cell types Another step of the method of the present disclosure may include differentiating the cells into differentiated cells. The differentiating step may be performed according to any method known in the art. For example, human iPSCs are differentiated into definitive endoderm using various treatments including activin and B27 supplement (Life Technologies). The definitive endoderm is further differentiated into hepatocytes, the treatments including FGF4, HGF, BMP2, BMP4, oncostatin M, dexamethasone, etc. (Duan et al, Stem Cells, 2010; 28: 674-686; Ma et al, Stem Cells Translational Medicine, 2013; 2: 409-419). In another embodiment, the differentiating step may be performed according to Sawitza et al, Sci Rep. 2015; 5: 13320. The differentiated cells may be any somatic cells of a mammal, for example, a human. In some embodiments, somatic cells include endocrine epithelial cells (e.g., thyroid hormone-secreting cells, adrenal cortical cells), exocrine epithelial cells (e.g., salivary gland mucous cells, prostate cells), hormone-secreting cells (e.g., anterior pituitary cells, pancreatic islet cells), keratinized epithelial cells (e.g., epidermal keratinocytes), moist stratified barrier epithelial cells, sensory transduction cells (e.g., photoreceptors), autonomic nerve cells, sensory and peripheral neuron supporting cells (e.g., Schwann cells), central nervous system neurons, and the like. The cell may be a fibroblast, a glial cell (e.g., astrocyte, oligodendrocyte), a lens cell, an adipocyte, a kidney cell, a barrier function cell (e.g., duct cell), an extracellular matrix cell, a contractile cell (e.g., skeletal muscle cell, cardiac muscle cell, smooth muscle cell), a blood cell (e.g., red blood cell), an immune system cell (e.g., megakaryocyte, microglial cell, neutrophil, mast cell, T cell, B cell, natural killer cell), a germ cell (e.g., sperm cell), a nurse cell, or an interstitial cell.
[0143] V. Formulation and Administration Formulation and Delivery for Gene Editing Guide RNAs, polynucleotides as described herein, e.g., polynucleotides encoding tolerogenic factors or polynucleotides encoding endonucleases, and endonucleases, can be formulated and delivered to cells in any manner known in the art.
[0144] The guide RNA and / or polynucleotide may be formulated with pharma- ceutically acceptable excipients, such as carriers, solvents, stabilizers, adjuvants, diluents, etc., depending on the particular mode of administration and dosage form. The guide RNA and / or polynucleotide composition may be formulated to reach a physiologically compatible pH, and a pH range of about pH 3 to about pH 11, about pH 3 to about pH 7, depending on the formulation and route of administration. In some cases, the pH may be adjusted to a range of about pH 5.0 to about pH 8. In some cases, the composition may include a therapeutically effective amount of at least one compound as described herein, along with one or more pharma-ceutically acceptable excipients. Optionally, the composition may include a combination of compounds described herein, may include a second active ingredient useful in the treatment or prevention of bacterial growth (e.g., but not limited to, an antibacterial or antimicrobial agent), or may include a combination of reagents of the present disclosure.
[0145] Suitable excipients include carrier molecules, including large, slowly metabolized macromolecules such as, for example, proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Other exemplary excipients can include antioxidants (such as, but not limited to, ascorbic acid), chelating agents (such as, but not limited to, EDTA), carbohydrates (such as, but not limited to, dextrin, hydroxyalkylcellulose, and hydroxyalkylmethylcellulose), stearic acid, liquids (such as, but not limited to, oils, water, saline, glycerol, and ethanol), wetting or emulsifying agents, pH buffering substances, and the like.
[0146] The guide RNA polynucleotide (RNA or DNA) and / or endonuclease polynucleotide (RNA or DNA) may be delivered by viral or non-viral delivery vehicles known in the art. Alternatively, the endonuclease polypeptide may be delivered by viral or non-viral delivery vehicles known in the art, such as electroporation or lipid nanoparticles. In further alternative aspects, the DNA endonuclease may be delivered as one or more polypeptides, alone or pre-complexed with one or more guide RNAs, or one or more crRNAs in combination with tracrRNA.
[0147] Polynucleotide can be delivered by non-viral vehicle, including but not limited to nanoparticles, liposomes, ribonucleoproteins, positively charged peptides, small RNA conjugates, aptamer-RNA chimeras, and RNA-fusion protein complexes.Some exemplary non-viral delivery vehicles are described in Peer and Lieberman, Gene Therapy, 2011, 18:1127-1133 (focusing on the non-viral delivery vehicle for siRNA, which is also useful for the delivery of other polynucleotides).
[0148] With respect to the polynucleotides of the present disclosure, formulations may be selected from any of those taught, for example, in International Application No. PCT / US2012 / 069610.
[0149] Polynucleotides such as guide RNAs, sgRNAs, and mRNAs encoding endonucleases can be delivered to cells or subjects by lipid nanoparticles (LNPs).
[0150] LNP refers to any particle having a diameter of less than 1000 nm, less than 500 nm, less than 250 nm, less than 200 nm, less than 150 nm, less than 100 nm, less than 75 nm, less than 50 nm, or less than 25 nm. Alternatively, nanoparticles can range in size from 1-1000 nm, 1-500 nm, 1-250 nm, 25-200 nm, 25-100 nm, 35-75 nm, or 25-60 nm.
[0151] LNPs can be made from cationic, anionic, or neutral lipids. Neutral lipids such as the membrane fusogenic phospholipid DOPE or membrane component cholesterol can be included in LNPs as "helper lipids" that enhance transfection activity and nanoparticle stability. The limitations of cationic lipids include poor stability and rapid clearance, as well as low efficacy due to the occurrence of inflammatory or anti-inflammatory responses.
[0152] LNPs can also be composed of hydrophobic lipids, hydrophilic lipids, or both hydrophobic and hydrophilic lipids.
[0153] Any lipid or combination of lipids known in the art can be used to produce LNPs. Examples of lipids used to produce LNPs are DOTMA, DOSPA, DOTAP, DMRIE, DC-cholesterol, DOTAP-cholesterol, GAP-DMORIE-DPyPE, and GL67A-DOPE-DMPE-polyethylene glycol (PEG). Examples of cationic lipids are 98N12-5, C12-200, DLin-KC2-DMA (KC2), DLin-MC3-DMA (MC3), XTC, MD1, and 7C1. Examples of neutral lipids are DPSC, DPPC, POPC, DOPE, and SM. Examples of PEG-modified lipids are PEG-DMG, PEG-CerC14, and PEG-CerC20.
[0154] Lipids can be combined in any number of molar ratios to produce LNPs. In addition, polynucleotides can be combined with lipids in a wide range of molar ratios to produce LNPs.
[0155] Recombinant adeno-associated virus (AAV) vectors can be used for delivery. Techniques for generating rAAV particles in which the AAV genome to be packaged, including the polynucleotide to be delivered, the rep and cap genes, and helper virus functions, are provided to cells are standard in the art. The production of rAAV usually requires the presence of the following components in a single cell (herein designated as a packaging cell): the rAAV genome, the AAV rep and cap genes separated from (i.e., not in) the rAAV genome, and the helper virus functions. The AAV rep and cap genes can be from any AAV serotype from which the recombinant virus can be derived, and can be from an AAV serotype different from the rAAV genome ITRs, including, but not limited to, the AAV serotypes described herein. The production of pseudotyped rAAV is disclosed, for example, in International Patent Application Publication No. WO 01 / 83692.
[0156] Formulation and Administration of Cells, E.g., Universal Donor Cells Genetically modified cells as described herein, e.g., universal donor cells, can be formulated and administered to a subject by any manner known in the art.
[0157] The terms "administer", "introduce", "implant", "engraft" and "transplant" are used interchangeably in the context of placement of cells, e.g., progenitor cells, into a subject by a method or route that results in at least partial localization of the introduced cells at a desired site. Cells, e.g., progenitor cells, or their differentiated progeny, can be administered by any suitable route that results in delivery to a desired location in a subject where at least a portion of the implanted cells or components of the cells remain viable. The survival period of the cells after administration to a subject can be as short as a few hours, e.g., 24 hours, to several days, to as long as several years, or for the lifespan of the subject, i.e., long-term engraftment.
[0158] Genetically modified cells as described herein, e.g., universal donor cells, may be viable for a longer period of time following administration to a subject than that of unmodified cells.
[0159] In some embodiments, compositions comprising cells as described herein may be administered by a suitable route, which may include, for example, intravenous administration as a bolus over a period of time or by continuous infusion. In some embodiments, intravenous administration may be performed by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intraarticular, intrasynovial, or intrathecal routes. In some embodiments, the compositions may be in solid, aqueous, or liquid form. In some embodiments, the aqueous or liquid form may be sprayed or lyophilized. In some embodiments, the sprayed or lyophilized form may be reconstituted with an aqueous or liquid solution.
[0160] The cell compositions may also be emulsified or presented as liposomal compositions, provided that the emulsification procedure does not adversely affect cell viability. The cells and any other active ingredients may be mixed with excipients that are pharma- ceutically acceptable and compatible with the active ingredients, and in amounts suitable for use in the therapeutic methods described herein.
[0161] Additional agents contained in the cell composition may include pharma- ceutically acceptable salts of the components. Pharmaceutically acceptable salts include acid addition salts (formed with free amino groups of the polypeptide) formed with inorganic acids such as, for example, hydrochloric acid or phosphoric acid, or organic acids such as acetic acid, tartaric acid, mandelic acid, etc. Salts formed with free carboxyl groups may also be derived from inorganic bases such as, for example, sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, or ferric hydroxide, and organic bases such as isopropylamine, trimethylamine, 2-ethylaminoethanol, histidine, procaine, etc.
[0162] Physiologically acceptable carriers are well known in the art. Exemplary liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredient and water, or that contain buffers such as sodium phosphate, saline, or both at physiological pH values, such as phosphate-buffered saline. In addition, aqueous carriers can contain two or more buffer salts, as well as salts such as sodium chloride and potassium chloride, dextrose, polyethylene glycol, and other solutes. Liquid compositions can also contain liquid phases in addition to and in addition to water. Examples of such additional liquid phases are glycerin, vegetable oils such as cottonseed oil, and water-oil emulsions. The amount of active compound used in the cell composition that is effective in treating a particular disorder or condition can depend on the nature of the disorder or condition, and can be determined by standard clinical procedures.
[0163] In some embodiments, the composition comprising the cells may be administered to a subject, e.g., a human subject, having, suspected of having, or at risk for a disease. In some embodiments, the composition may be administered to a subject that does not have, is not suspected of having, or is not at risk for a disease. In some embodiments, the subject is a healthy human. In some embodiments, a subject, e.g., a human subject, having, is suspected of having, or is at risk for a genetically inherited disease. In some embodiments, the subject is suffering from or at risk for developing a symptom of a disease.
[0164] VI. Certain Compositions and Methods of the Disclosure Accordingly, the present disclosure relates to, among other things, the following non-limiting compositions and methods:
[0165] In a first composition, Composition 1, the disclosure provides a composition comprising cells comprising: (i) at least one genetic modification within or near at least one gene encoding one or more MHC-I and MHC-II human leukocyte antigens or other components or transcriptional regulators of the MHC-I or MHC-II complexes; (ii) at least one genetic modification that increases expression of at least one polynucleotide encoding a tolerogenic factor relative to an unmodified cell; and (iii) at least one genetic modification that increases or decreases expression of at least one gene encoding a survival factor relative to an unmodified cell.
[0166] In another composition, composition 2, the disclosure provides a composition comprising a cell comprising: (i) at least one deletion and / or insertion of at least one base pair within or near at least one gene encoding one or more MHC-I and MHC-II human leukocyte antigens or other components or transcriptional regulators of the MHC-I or MHC-II complexes; and (ii) at least one insertion of a polynucleotide encoding at least one tolerogenic factor at a site partially overlapping, completely overlapping, or contained within the site of the gene deletion of (i).
[0167] In another composition, composition 3, the disclosure provides a composition comprising cells that contain at least one genetic modification that increases or decreases expression of at least one gene encoding a survival factor relative to an unmodified cell.
[0168] In another composition, composition 4, the disclosure provides a composition as provided in composition 1, wherein the genetic modification in (i) is a deletion.
[0169] In another composition, composition 5, the disclosure provides a composition as provided in composition 1, wherein the genetic modification of (ii) is an insertion of a polynucleotide encoding an immune tolerogenic factor at a safe harbor locus or a site that partially overlaps, completely overlaps, or is contained within the site of the genetic modification of (i).
[0170] In another composition, Composition 6, the disclosure provides a composition as provided in Composition 1, wherein the (i) genetic modification is a deletion of genes encoding one or more MHC-I and MHC-II human leukocyte antigens or other components or transcriptional regulators of the MHC-I or MHC-II complexes; and the (ii) genetic modification is an insertion of a polynucleotide encoding at least one tolerogenic factor at a site that partially overlaps, completely overlaps, or is contained within the site of the genetic modification of (i).
[0171] In another composition, Composition 7, the disclosure provides a composition as provided in any one of Compositions 1, 2, or 4-6, wherein the at least one gene encoding one or more MHC-I and MHC-II human leukocyte antigens or other components or transcriptional regulators of the MHC-I or MHC-II complexes is one or more of an MHC-I gene (e.g., HLA-A, HLA-B, and HLA-C), an MHC-II gene (e.g., HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, and HLA-DR), or a gene encoding a transcriptional regulator of MHC-I or MHC-II or other components of the MHC-I complex (e.g., B2M, NLRC5, and CIITA).
[0172] In another composition, Composition 8, the disclosure provides a composition as provided in any one of Compositions 1, 2, or 4-6, wherein at least one gene encoding one or more MHC-I and MHC-II human leukocyte antigens or other components or transcriptional regulators of the MHC-I or MHC-II complexes is one or more of HLA-A, HLA-B, HLA-C, B2M, or CIITA.
[0173] In another composition, composition 9, the disclosure provides a composition as provided in composition 1 or 2, wherein (i) is a deletion in or near one or more of HLA-A, HLA-B, HLA-C, B2M, or CIITA.
[0174] In another composition, composition 10, the disclosure provides a composition as provided in composition 9, wherein (i) is a deletion in or near HLA-A, a deletion in or near HLA-B, a deletion in or near HLA-C, or a deletion in or near B2M.
[0175] In another composition, composition 11, the disclosure provides a composition as provided in composition 9, wherein (i) is a deletion in or near HLA-A, a deletion in or near HLA-B, a deletion in or near HLA-C, or a deletion in or near CIITA.
[0176] In another composition, composition 12, the present disclosure provides a composition as provided in any one of compositions 1, 2, or 4-11, wherein the at least one polynucleotide encoding a tolerogenic factor is one or more polynucleotides encoding one or more of HLA-E, HLA-G, CTLA-4, CD47, or PD-L1.
[0177] In another composition, composition 13, the disclosure provides a composition as provided in composition 12, wherein (i) is a deletion within or near B2M, and (ii) is an insertion of a polynucleotide encoding PD-L1 at a site that partially overlaps, completely overlaps, or is contained within the deletion in (i).
[0178] In another composition, composition 14, the disclosure provides a composition as provided in composition 12, wherein (i) is a deletion in or near HLA-A, a deletion in or near HLA-B, or a deletion in or near HLA-C, and (ii) is an insertion of a polynucleotide encoding HLA-G at a site that partially overlaps, completely overlaps, or is contained within the deletion in (i) (e.g., an HLA-A deletion).
[0179] In another composition, composition 15, the disclosure provides a composition as provided in composition 12, wherein (i) is a deletion in or near HLA-A, a deletion in or near HLA-B, a deletion in or near HLA-C, or a deletion in or near CIITA, and (ii) is an insertion of a polynucleotide encoding HLA-G at a site that partially overlaps, completely overlaps, or is contained within the deletion in or near HLA-A and an insertion of a polynucleotide encoding CD47 at a site that partially overlaps, completely overlaps, or is contained within the deletion in or near CIITA.
[0180] In another composition, composition 16, the present disclosure provides a composition as provided in any one of compositions 1, or 3-15, wherein the at least one gene encoding a survival factor is one or more genes encoding one or more of ZNF143, TXNIP, FOXO1, JNK, or MANF.
[0181] In another composition, composition 17, the disclosure provides a composition as provided in any one of compositions 1 or 3-16, wherein the genetic modification that increases or decreases expression of a gene encoding a survival factor, relative to an unmodified cell, is an insertion of a polynucleotide encoding MANF, e.g., at a safe harbor locus.
[0182] In another composition, composition 18, the disclosure provides a composition as provided in any one of compositions 1, or 3-16, wherein the genetic modification that increases or decreases expression of a gene encoding a survival factor relative to unmodified cells is a deletion in or near the ZNF143, TXNIP, FOXO1, or JNK gene that reduces or eliminates expression of the ZNF143, TXNIP, FOXO1, or JNK gene relative to unmodified cells.
[0183] In another composition, composition 19, the disclosure provides a composition as provided in any one of compositions 1-18, wherein the cell further comprises an exogenous polynucleotide that is not integrated into the genomic DNA of the cell.
[0184] In another composition, composition 20, the present disclosure provides a composition as provided in composition 19, wherein the exogenous polynucleotide encodes HLA-E, HLA-G, CTLA-4, CD47, MANF, and / or PD-L1.
[0185] In another composition, composition 21, the disclosure provides a composition as provided in any one of compositions 1-20, wherein the cell further comprises increased expression of one or more safety switches, relative to an unmodified cell.
[0186] In another composition, composition 22, the present disclosure provides a composition as provided in composition 21, wherein the safety switch is herpes simplex virus-1 thymidine kinase (HSV-tk) or inducible caspase-9.
[0187] In another composition, composition 23, the disclosure provides a composition as provided in composition 21 or 22, wherein the increased expression of one or more safety switches results from genetic insertion of a polynucleotide encoding a safety switch protein, e.g., into a safe harbor locus.
[0188] In another composition, composition 24, the disclosure provides a composition as provided in any one of compositions 5, 17, or 23, wherein the safe harbor locus is selected from the group consisting of AAVS1 (PPP1 R12C), ALB, Angptl3, ApoC3, ASGR2, CCR5, FIX(F9), G6PC, Gys2, HGD, Lp(a), Pcsk9, Serpinal, TF, and TTR.
[0189] In another composition, composition 25, the disclosure provides a composition as provided in any one of compositions 1-24, wherein the cells further comprise an additional genetic modification that reduces expression of any additional gene.
[0190] In another composition, composition 26, the disclosure provides a composition as provided in any one of compositions 1-25, wherein the genetic modification, gene deletion, or gene insertion is produced by delivering an endonuclease and a guide RNA (gRNA) to a cell.
[0191] In another composition, composition 27, the disclosure provides a method for the preparation of a cytoplasmic endonuclease comprising administering to a patient a cytoplasmic endonuclease selected from the group consisting of Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas100, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cm r4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, or Cpf1 endonuclease; homologs thereof, recombinant, codon-optimized, or modified versions of naturally occurring molecules thereof, and combinations thereof.
[0192] In another composition, composition 28, the disclosure provides a composition as provided in composition 27, wherein the endonuclease is Cas9, optionally S. pyogenes Cas9, or a variant thereof comprising an N-terminal SV40 NLS and a C-terminal SV40 NLS.
[0193] In another composition, composition 29, the present disclosure provides a composition as provided in composition 26, wherein the weight ratio of the gRNA to the endonuclease is 1:1.
[0194] In another composition, composition 30, the disclosure provides a composition as provided in any one of compositions 2, 5, 6, 12-15, 17, 19, or 23, wherein the polynucleotide comprises an exogenous promoter.
[0195] In another composition, composition 31, the present disclosure provides a composition as provided in composition 30, wherein the exogenous promoter is a CMV, EFla, PGK, CAG, UBC, or other constitutive, inducible, time-specific, tissue-specific, or cell type-specific promoter.
[0196] In another composition, composition 32, the present disclosure provides a composition as provided in composition 31, wherein the exogenous promoter is a CAG promoter.
[0197] In another composition, composition 33, the present disclosure provides a composition as provided in any one of compositions 1-32, wherein the cells are stem cells (eg, human stem cells).
[0198] In another composition, composition 34, the disclosure provides a composition as provided in any one of compositions 1-33, wherein the cell is an embryonic stem cell (ESC), an adult stem cell (ASC), an induced pluripotent stem cell (iPSC), or a hematopoietic stem or progenitor cell (HSPC).
[0199] In another composition, composition 35, the present disclosure provides a composition as provided in any one of compositions 1-32, wherein the cell is a differentiated cell.
[0200] In another composition, composition 36, the disclosure provides a composition as provided in any one of compositions 1-32 or 35, wherein the cell is a somatic cell.
[0201] In a first method, Method 1, the disclosure provides methods of making modified cells comprising: (i) introducing at least one genetic modification within or near at least one gene encoding one or more MHC-I and MHC-II human leukocyte antigens or other components or transcriptional regulators of the MHC-I or MHC-II complexes; (ii) introducing at least one genetic modification that increases expression of at least one polynucleotide encoding a tolerogenic factor in the cell; and (iii) introducing at least one genetic modification that increases or decreases expression of at least one gene encoding a survival factor in a universal donor cell.
[0202] In another method, Method 2, the disclosure provides a method of generating a universal donor cell comprising: (i) introducing at least one deletion of at least one region of genomic DNA within or near at least one gene encoding one or more MHC-I and MHC-II human leukocyte antigens or other components or transcriptional regulators of the MHC-I or MHC-II complexes; and (ii) introducing at least one insertion of at least one polynucleotide encoding an immune tolerogenic factor at a site partially overlapping, completely overlapping, or contained within the site of the deletion of (i).
[0203] In another method, method 3, the disclosure provides a method of generating a universal donor cell comprising introducing at least one genetic modification that increases or decreases expression of at least one gene encoding a survival factor.
[0204] In another method, method 4, the disclosure provides a method as provided in method 1, wherein the genetic modification in (i) is a deletion.
[0205] In another method, method 5, the disclosure provides a method as provided in method 1, wherein the genetic modification of (ii) is an insertion of a polynucleotide encoding an immune tolerogenic factor at a safe harbor locus or a site that partially overlaps, completely overlaps, or is contained within the site of the genetic modification of (i).
[0206] In another method, method 6, the disclosure provides a method as provided in method 1, wherein the genetic modification of (i) is a deletion of genes encoding one or more MHC-I and MHC-II human leukocyte antigens or other components or transcriptional regulators of the MHC-I or MHC-II complexes; and the genetic modification of (ii) is an insertion of a polynucleotide encoding at least one tolerogenic factor at a site that partially overlaps, completely overlaps, or is contained within the site of the genetic modification of (i).
[0207] In another method, Method 7, the disclosure provides a method as provided in any one of Methods 1, 2, or 4-6, wherein the at least one gene encoding one or more MHC-I and MHC-II human leukocyte antigens or other components or transcriptional regulators of the MHC-I or MHC-II complexes is one or more of a MHC-I gene (e.g., HLA-A, HLA-B, and HLA-C), an MHC-II gene (e.g., HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, and HLA-DR), or a gene encoding a transcriptional regulator of MHC-I or MHC-II (e.g., B2M, NLRC5, and CIITA).
[0208] In another method, Method 8, the disclosure provides a method as provided in any one of Methods 1, 2, or 4-6, wherein at least one gene encoding one or more MHC-I and MHC-II human leukocyte antigens or other components or transcriptional regulators of the MHC-I or MHC-II complexes is one or more of HLA-A, HLA-B, HLA-C, B2M, or CIITA.
[0209] In another method, method 9, the disclosure provides a method as provided in method 1 or 2, wherein (i) is a deletion in or near one or more of HLA-A, HLA-B, HLA-C, B2M, or CIITA.
[0210] In another method, method 10, the disclosure provides a method as provided in method 9, wherein (i) is a deletion in or near HLA-A, a deletion in or near HLA-B, a deletion in or near HLA-C, and a deletion in or near B2M.
[0211] In another method, method 11, the disclosure provides a method as provided in method 9, wherein (i) is a deletion in or near HLA-A, a deletion in or near HLA-B, a deletion in or near HLA-C, and a deletion in or near CIITA.
[0212] In another method, method 12, the disclosure provides a method as provided in any one of methods 1, 2, or 4-11, wherein the at least one polynucleotide encoding a tolerogenic factor is one or more polynucleotides encoding one or more of HLA-E, HLA-G, CTLA-4, CD47, or PD-L1.
[0213] In another method, Method 13, the disclosure provides a method as provided in Method 12, wherein (i) is a deletion within or near B2M, and (ii) is an insertion of a polynucleotide encoding PD-L1 at a site that partially overlaps, completely overlaps, or is contained within the deletion in (i).
[0214] In another method, method 14, the disclosure provides a method as provided in method 12, wherein (i) is a deletion in or near HLA-A, a deletion in or near HLA-B, and a deletion in or near HLA-C, and (ii) is an insertion of a polynucleotide encoding HLA-G at a site that partially overlaps, completely overlaps, or is contained within the deletion in (i) (e.g., the HLA-A deletion).
[0215] In another method, method 15, the disclosure provides a method as provided in method 12, wherein (i) is a deletion in or near HLA-A, a deletion in or near HLA-B, a deletion in or near HLA-C, and a deletion in or near CIITA, and (ii) is an insertion of a polynucleotide encoding HLA-G at a site that partially overlaps, completely overlaps, or is contained within the deletion in or near HLA-A and an insertion of a polynucleotide encoding CD47 at a site that partially overlaps, completely overlaps, or is contained within the deletion in or near CIITA.
[0216] In another method, method 16, the disclosure provides a method as provided in any one of methods 1 or 3-15, wherein the at least one gene encoding a survival factor is one or more genes encoding one or more of ZNF143, TXNIP, FOXO1, JNK, or MANF.
[0217] In another method, method 17, the disclosure provides a method as provided in any one of methods 1 or 3-16, wherein the genetic modification that increases or decreases expression of a gene encoding a survival factor is insertion of a polynucleotide encoding MANF, e.g., at a safe harbor locus.
[0218] In another method, method 18, the disclosure provides a method as provided in any one of methods 1 or 3-16, wherein the genetic modification that increases or decreases expression of a gene encoding a survival factor is a deletion in or near the ZNF143, TXNIP, FOXO1, or JNK gene that reduces or eliminates expression of the ZNF143, TXNIP, FOXO1, or JNK gene relative to an unmodified cell.
[0219] In another method, method 19, the disclosure provides a method as provided in any one of methods 1-18, wherein the cell is a stem cell (eg, a human stem cell).
[0220] In another method, method 20, the disclosure provides a method as provided in any one of methods 1-19, wherein the cell is an embryonic stem cell (ESC), an adult stem cell (ASC), an induced pluripotent stem cell (iPSC), or a hematopoietic stem or progenitor cell (HSPC).
[0221] In another method, method 21, the disclosure provides a method as provided in any one of methods 1-18, wherein the cell is a differentiated cell.
[0222] In another method, method 22, the disclosure provides a method as provided in any one of methods 1-18 or 21, wherein the cell is a somatic cell.
[0223] In another method, method 23, the disclosure provides a method as provided in any one of methods 1-22, wherein the method further comprises introducing an exogenous polynucleotide into the cell that does not integrate into the genomic DNA of the cell.
[0224] In another method, method 24, the disclosure provides a method as provided in method 23, wherein the exogenous polynucleotide encodes HLA-E, HLA-G, CTLA-4, CD47, MANF, and / or PD-L1.
[0225] In another method, method 25, the disclosure provides a method as provided in any one of methods 1-24, wherein the method further comprises increasing expression of one or more safety switches relative to an unmodified cell.
[0226] In another method, method 26, the disclosure provides the method as provided in method 25, wherein the safety switch is herpes simplex virus-1 thymidine kinase (HSV-tk) or inducible caspase-9.
[0227] In another method, method 27, the disclosure provides a method as provided in methods 25 or 26, wherein increased expression of the one or more safety switches results from genetic insertion of a polynucleotide encoding a safety switch, e.g., into a safe harbor locus.
[0228] In another method, method 28, the disclosure provides a method as provided in any one of methods 5, 17, or 27, wherein the safe harbor locus is selected from the group consisting of AAVS1 (PPP1 R12C), ALB, Angptl3, ApoC3, ASGR2, CCR5, FIX(F9), G6PC, Gys2, HGD, Lp(a), Pcsk9, Serpinal, TF, and TTR.
[0229] In another method, method 29, the disclosure provides a composition as provided in any one of methods 1-28, wherein the method further comprises introducing an additional genetic modification that reduces expression of any additional gene.
[0230] In another method, method 30, the disclosure provides a method as provided in any one of methods 1-29, wherein the genetic modification, deletion, or insertion is generated by delivering an endonuclease and at least one guide RNA (gRNA) to the cell.
[0231] In another method, method 31, the disclosure provides that the endonuclease is selected from the group consisting of Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas100, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cm r4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, or Cpf1 endonuclease; homologs thereof, recombinant naturally occurring molecules thereof, codon optimized, or modified versions thereof, and combinations thereof.
[0232] In another method, method 32, the disclosure provides a method as provided in method 31, wherein the endonuclease is Cas9, optionally S. pyogenes Cas9, or a variant thereof comprising an N-terminal SV40 NLS and a C-terminal SV40 NLS.
[0233] In another method, method 33, the present disclosure provides a method as provided in method 30, wherein the weight ratio of said gRNA to said endonuclease is 1:1.
[0234] In another method, method 34, the disclosure provides a method as provided in any one of methods 2, 5, 6, 12-15, 17, 23, 25, or 27, wherein the polynucleotide comprises an exogenous promoter.
[0235] In another method, method 35, the disclosure provides a method as provided in method 34, wherein the exogenous promoter is a CMV, EFla, PGK, CAG, UBC, or other constitutive, inducible, time-specific, tissue-specific, or cell type-specific promoter.
[0236] In another method, method 36, the present disclosure provides a method as provided in method 35, wherein the exogenous promoter is a CAG promoter.
[0237] In another method, method 37, the present disclosure provides a method comprising administering to a subject a composition of cells as provided in any one of compositions 1-36 or a composition comprising a plurality of cells produced by any one of methods 1-36.
[0238] In another method, Method 38, the disclosure provides a method comprising: (i) obtaining a composition of cells as provided in any one of Compositions 1-34; (ii) differentiating the cells into lineage-restricted cells or fully differentiated cells; and (iii) administering the lineage-restricted cells or fully differentiated cells to a subject in need thereof.
[0239] In another method, method 39, the disclosure provides a method as provided in method 37 or 38, wherein the subject is a human having, suspected of having, or at risk of having the disease.
[0240] In another method, method 40, the disclosure provides a method as provided in method 39, wherein the disease is a genetically inherited disease.
[0241] In another method, method 41, the disclosure provides a method as provided in methods 39 or 40, wherein the cells further comprise a genetic modification that reduces expression of a gene or protein associated with the disease.
[0242] In another method, method 42, the disclosure provides a method as provided in any one of methods 39-41, wherein the genetic modification is capable of treating a disease or a symptom of a disease.
[0243] In another method, method 43, the disclosure provides a method as provided in any one of methods 37-42, wherein the cells are obtained from a source other than the subject.
[0244] In another method, method 44, the disclosure provides a method of generating a universal donor cell comprising: (i) introducing a deletion and / or insertion of at least one base pair in the genome of the cell at a site within or near at least one gene encoding one or more of the MHC-I or MHC-II human leukocyte antigens, or components or transcriptional regulators of the MHC-I or MHC-II complexes; and (ii) introducing an insertion of at least one polynucleotide encoding a tolerogenic factor at a site in the genome of the cell that partially overlaps, completely overlaps, or is contained within the site of (i), thereby generating a universal donor cell.
[0245] In another method, method 45, the disclosure provides a method of generating a universal donor cell comprising: (i) introducing a deletion and / or insertion of at least one base pair in the genome of the cell at a site within or near at least one gene encoding one or more of the MHC-I or MHC-II human leukocyte antigens, or components or transcriptional regulators of the MHC-I or MHC-II complexes; and (ii) genetically modifying the cell by introducing an insertion of at least one polynucleotide encoding a tolerogenic factor at a safe harbor locus in the genome of the cell, thereby generating a universal donor cell.
[0246] In another method, method 46, the disclosure provides a method as provided in methods 44 or 45, wherein the universal donor cells have increased immune evasion and / or cell survival compared to unmodified cells.
[0247] In another method, method 47, the disclosure provides a method as provided in any one of methods 44-46, wherein at least one gene encoding one or more MHC-I or MHC-II human leukocyte antigens, or components or transcriptional regulators of the MHC-I or MHC-II complexes, is an MHC-I gene selected from HLA-A, HLA-B, or HLA-C, an MHC-II gene selected from HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, or HLA-DR, or a gene selected from B2M, NLRC5, CIITA, RFX5, RFXAP, or RFXANK.
[0248] In another method, method 48, the disclosure provides a method as provided in any one of methods 44-47, wherein the at least one polynucleotide encoding a tolerogenic factor is one or more polynucleotides encoding one or more of PD-L1, HLA-E, HLA-G, CTLA-4, or CD47.
[0249] In another method, method 49, the present disclosure provides a method as provided in any one of methods 44-48, wherein at least one polynucleotide encoding an immune tolerogenic factor is operably linked to an exogenous promoter.
[0250] In another method, method 50, the disclosure provides a method as provided in method 49, wherein the exogenous promoter is a constitutive, inducible, time-specific, tissue-specific, or cell type-specific promoter, and the constitutive promoter is a CMV, EFla, PGK, CAG, or UBC promoter.
[0251] In another method, method 51, the disclosure provides a method as provided in any one of methods 44 to 50, wherein (i) the deletion and / or insertion is in or near B2M and (ii) the insertion is a polynucleotide encoding PD-L1 or HLA-E.
[0252] In another method, method 52, the disclosure provides a method as provided in any one of methods 44-51, wherein the method further comprises introducing into the unmodified cell at least one genetic modification that increases or decreases expression of at least one survival factor.
[0253] In another method, method 53, the disclosure provides a method as provided in method 52, wherein the at least one genetic modification that increases or decreases expression of at least one survival factor is an insertion of a polynucleotide encoding MANF, which increases expression of MANF relative to unmodified cells; or a deletion and / or insertion of at least one base pair within or near a gene encoding ZNF143, TXNIP, FOXO1, or JNK, which decreases or eliminates expression of ZNF143, TXNIP, FOXO1, or JNK relative to unmodified cells.
[0254] In another method, method 54, the disclosure provides a method as provided in method 53, wherein the polynucleotide encoding MANF is inserted into a safe harbor locus or into a gene belonging to MHC-I, MHC-II, or a transcriptional regulator of MHC-I or MHC-II.
[0255] In another method, method 55, the disclosure provides a method as provided in any one of methods 44-54, wherein the genetic modification comprises delivering at least one RNA-guided endonuclease system to the cell.
[0256] In another method, method 56, the present disclosure provides a method as provided in method 55, wherein the at least one RNA-guided endonuclease system is a CRISPR system comprising a CRISPR nuclease and a guide RNA.
[0257] In another method, method 57, the disclosure provides a method as provided in method 56, wherein the CRISPR nuclease is Cas9, Cpf1, a homolog thereof, a modified version thereof, a codon-optimized version thereof, or any combination thereof.
[0258] In another method, method 58, the disclosure provides a method as provided in method 56 or 57, wherein the CRISPR nuclease is S. pyogenes Cas9.
[0259] In another method, method 59, the disclosure provides a method as provided in any one of methods 56-58, wherein the CRISPR nuclease comprises an N-terminal nuclear localization signal (NLS) and / or a C-terminal NLS.
[0260] In another method, method 60, the present disclosure provides a method as provided in any one of methods 56-59, wherein the CRISPR nuclease and guide RNA are present in a 1:1 weight ratio.
[0261] In another method, method 61, the disclosure provides a method as provided in any one of methods 44 or 46-60, wherein (i) the deletion and / or insertion is within or near the B2M locus and (ii) the insertion is a polynucleotide encoding PD-L1.
[0262] In another method, method 62, the disclosure provides a method as provided in method 61, wherein the guide RNA used for (i) and (ii) comprises a nucleotide sequence comprising at least one of SEQ ID NOs: 1-3 or 35-44.
[0263] In another method, Method 63, the disclosure provides a method as provided in Methods 61 or 62, wherein the polynucleotide encoding PD-L1 is flanked by a nucleotide sequence having sequence homology to a region located to the left of the site in (a)(i) and a nucleotide sequence having sequence homology to a region located to the right of the site in (b)(i).
[0264] In another method, method 64, the disclosure provides a method as provided in method 63, wherein a polynucleotide encoding PD-L1 is inserted into the B2M locus within 50 base pairs of the site in (i).
[0265] In another method, method 65, the present disclosure provides a method as provided in methods 63 or 64, wherein (a) consists essentially of the nucleotide sequence of SEQ ID NO:13, and (b) consists essentially of the nucleotide sequence of SEQ ID NO:19.
[0266] In another method, Method 66, the disclosure provides a method as provided in any one of Methods 61-65, wherein the polynucleotide encoding PD-L1 is operably linked to an exogenous promoter, optionally wherein the exogenous promoter is a CAG promoter.
[0267] In another method, method 67, the present disclosure provides a method as provided in any one of methods 44-66, where the cell is a mammalian cell, and optionally, the cell is a human cell.
[0268] In another method, method 68, the present disclosure provides a method as provided in any one of methods 44-67, wherein the cell is a stem cell.
[0269] In another method, method 69, the disclosure provides a method as provided in any one of methods 44 to 68, wherein the cell is a pluripotent stem cell (PSC), an embryonic stem cell (ESC), an adult stem cell (ASC), an induced pluripotent stem cell (iPSC), or a hematopoietic stem or progenitor cell (HSPC).
[0270] In another method, method 70, the present disclosure provides a method as provided in any one of methods 44-69, wherein the cell is a differentiated cell or a somatic cell.
[0271] In another method, method 71, the disclosure provides a method as provided in any one of methods 44-69, wherein the universal donor cells are capable of differentiating into lineage-restricted progenitor cells or fully differentiated somatic cells.
[0272] In another method, method 72, the disclosure provides a method as provided in method 71, wherein the lineage-restricted progenitor cell is a pancreatic endoderm progenitor cell, a pancreatic endocrine progenitor cell, a mesenchymal progenitor cell, a muscle progenitor cell, a blast cell, or a neural progenitor cell.
[0273] In another method, method 73, the present disclosure provides a method as provided in method 71, wherein the fully differentiated somatic cell is an endocrine cell such as a pancreatic beta cell, an epithelial cell, an endodermal cell, a macrophage, a hepatocyte, an adipocyte, a kidney cell, a blood cell, or an immune system cell.
[0274] In another composition, composition 37, the present disclosure provides a composition comprising a plurality of universal donor cells produced by a method as provided in any one of methods 44-73.
[0275] In another composition, composition 38, the present disclosure provides a method as provided in composition 37, wherein a plurality of universal donor cells can be maintained for a time and under conditions sufficient for the cells to undergo differentiation.
[0276] In another composition, composition 39, the disclosure provides a composition comprising a cell comprising: (i) at least one deletion within or near at least one gene encoding one or more MHC-I and MHC-II human leukocyte antigens, or a component or transcriptional regulator of the MHC-I or MHC-II complex; and (ii) at least one insertion of a polynucleotide encoding at least one tolerogenic factor at a site partially overlapping, completely overlapping, or contained within the site of the gene deletion of (i).
[0277] In another method, method 74, the disclosure provides a method comprising administering to a subject a plurality of universal donor cells of composition 37 or 38.
[0278] In another method, method 75, the disclosure provides a method for treating a subject in need thereof, comprising: (i) obtaining or having obtained a plurality of universal donor cells of composition 37 or 38 following differentiation into lineage-restricted progenitor cells or fully differentiated somatic cells; and (ii) administering to the subject the lineage-restricted progenitor cells or fully differentiated somatic cells.
[0279] In another method, method 76, the disclosure provides a method of obtaining cells for administration to a subject in need thereof, comprising: (i) obtaining or having obtained a universal donor cell of composition 37 or 38; and (ii) maintaining the universal donor cell for a time and under conditions sufficient for the cell to differentiate into a lineage-restricted progenitor cell or a fully differentiated somatic cell.
[0280] In another method, method 77, the disclosure provides a method as provided in method 75 or 76, wherein the lineage-restricted progenitor cell is a pancreatic endoderm progenitor cell, a pancreatic endocrine progenitor cell, a mesenchymal progenitor cell, a muscle progenitor cell, a blast cell, or a neural progenitor cell.
[0281] In another method, method 78, the disclosure provides a method as provided in method 75 or 76, wherein the fully differentiated somatic cell is an endocrine cell such as a pancreatic beta cell, an epithelial cell, an endodermal cell, a macrophage, a hepatocyte, an adipocyte, a kidney cell, a blood cell, or an immune system cell.
[0282] In another method, method 79, the disclosure provides a method as provided in any one of methods 74-78, wherein the subject is a human having, suspected of having, or at risk of having the disease.
[0283] In another method, method 80, the disclosure provides a method as provided in method 79, wherein the disease is a genetically inherited disease.
[0284] In another method, method 81, the disclosure provides a method for generating a universal donor cell, comprising delivering to a pluripotent stem cell (PSC) a vector comprising: (a) an RNA-guided nuclease; (b) a guide RNA (gRNA) that targets a target site in a beta-2-microglobulin (B2M) gene locus; and (c) a nucleic acid comprising: (i) a nucleotide sequence that is homologous to a region located to the left of the target site in the B2M gene locus, (ii) a nucleotide sequence that encodes an immune tolerogenic factor, and (iii) a nucleotide sequence that is homologous to a region located to the right of the target site in the B2M gene locus, wherein the B2M gene locus is cleaved at the target site and the nucleic acid is inserted into the B2M gene locus within 50 base pairs of the target site, thereby generating a universal donor cell, wherein the universal donor cell has increased immune evasion and / or cell survival compared to a PSC that does not comprise the nucleic acid inserted into the B2M gene locus.
[0285] In another method, method 82, the disclosure provides a method as provided in method 81, wherein the gRNA comprises a nucleotide sequence selected from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.
[0286] In another method, method 83, the present disclosure provides a method as provided in methods 81 or 82, wherein (i) consists essentially of the nucleotide sequence of SEQ ID NO:13, and (iii) consists essentially of the nucleotide sequence of SEQ ID NO:19.
[0287] In another method, method 84, the present disclosure provides a method as provided in any one of methods 81 to 83, wherein the tolerogenic factor is programmed death-ligand 1 (PD-L1) or human leukocyte antigen E (HLA-E).
[0288] In another method, method 85, the present disclosure provides a method as provided in any one of methods 81-84, wherein the nucleotide sequence encoding the tolerogenic factor is operably linked to an exogenous promoter.
[0289] In another method, method 86, the disclosure provides a method as provided in method 85, wherein the exogenous promoter is constitutive, cell type specific, tissue type specific, or temporally regulated.
[0290] In another method, method 87, the disclosure provides a method as provided in method 85 or 86, wherein the exogenous promoter is a CAG promoter.
[0291] In another method, method 88, the present disclosure provides a method as provided in any one of methods 81-87, wherein the vector is a plasmid vector.
[0292] In another method, method 89, the disclosure provides a method as provided in method 88, wherein the plasmid vector comprises the nucleotide sequence of SEQ ID NO:33 or SEQ ID NO:34.
[0293] In another method, method 90, the disclosure provides a method as provided in any one of methods 81-89, wherein the RNA-guided nuclease is a Cas9 nuclease.
[0294] In another method, method 91, the disclosure provides a method as provided in method 90, wherein the Cas9 nuclease is linked to at least one nuclear localization signal (NLS).
[0295] In another method, method 92, the disclosure provides a method as provided in method 90 or 91, wherein the Cas9 nuclease is a S. pyogenes Cas9.
[0296] In another method, method 93, the disclosure provides a method as provided in any one of methods 81-92, wherein the PSCs are embryonic stem cells (ESCs), adult stem cells (ASCs), induced pluripotent stem cells (iPSCs), or hematopoietic stem or progenitor cells (HSPCs).
[0297] In another method, method 94, the disclosure provides a method as provided in any one of methods 81-93, wherein the PSCs are human PSCs.
[0298] In another method, method 95, the disclosure provides a method for generating a universal donor cell, comprising delivering to a pluripotent stem cell (PSC) a vector comprising: (a) an RNA-guided nuclease; (b) a guide RNA (gRNA) that targets a target site in a beta-2-microglobulin (B2M) gene locus, where the gRNA comprises the nucleotide sequence of SEQ ID NO: 2; and (c) a nucleic acid comprising: (i) a nucleotide sequence that is homologous to a region located to the left of the target site in the B2M gene locus consisting essentially of SEQ ID NO: 13, (ii) a nucleotide sequence that encodes an immune tolerogenic factor, and (iii) a nucleotide sequence that is homologous to a region located to the right of the target site in the B2M gene locus consisting essentially of SEQ ID NO: 19, wherein the B2M gene locus is cleaved at the target site and the nucleic acid is inserted into the B2M gene locus within 50 base pairs of the target site, thereby generating a universal donor cell, wherein the universal donor cell has increased immune evasion and / or cell survival compared to a PSC that does not comprise the nucleic acid inserted into the B2M gene locus.
[0299] In another method, method 96, the disclosure provides a method as provided in method 95, wherein the tolerogenic factor is programmed death-ligand 1 (PD-L1) or human leukocyte antigen E (HLA-E).
[0300] In another method, method 97, the disclosure provides a method as provided in methods 95 or 96, wherein the nucleotide sequence encoding the tolerogenic factor is operably linked to an exogenous promoter.
[0301] In another method, method 98, the disclosure provides a method as provided in method 97, wherein the exogenous promoter is constitutive, cell type specific, tissue type specific, or temporally regulated.
[0302] In another method, method 99, the disclosure provides a method as provided in method 97 or 98, wherein the exogenous promoter is a CAG promoter.
[0303] In another method, method 100, the present disclosure provides a method as provided in any one of methods 95-99, wherein the vector is a plasmid vector.
[0304] In another method, method 101, the disclosure provides a method as provided in method 100, wherein the plasmid vector comprises the nucleotide sequence of SEQ ID NO:33 or SEQ ID NO:34.
[0305] In another method, method 102, the disclosure provides a method as provided in any one of methods 95-101, wherein the RNA-guided nuclease is a Cas9 nuclease.
[0306] In another method, method 103, the disclosure provides a method as provided in method 102, wherein the Cas9 nuclease is linked to at least one nuclear localization signal (NLS).
[0307] In another method, method 104, the disclosure provides a method as provided in method 102 or 103, wherein the Cas9 nuclease is a S. pyogenes Cas9.
[0308] In another method, method 105, the disclosure provides a method as provided in any one of methods 95 to 104, wherein the PSCs are embryonic stem cells (ESCs), adult stem cells (ASCs), induced pluripotent stem cells (iPSCs), or hematopoietic stem or progenitor cells (HSPCs).
[0309] In another method, method 106, the disclosure provides a method as provided in any one of methods 95-105, wherein the PSCs are human PSCs. EXAMPLES
[0310] VII. Examples The examples below describe the generation and characterization of universal donor cells according to the present disclosure. Table 1 lists immune tolerogenic factors and Table 2 lists survival factors that can be genetically modified in the cells. Figures 1A-1C show various gene editing strategies that can be utilized for immune evasion.
[0311] [Table 1]
[0312] [Table 2]
[0313] Example 1: Generation of B2M knockout IPSCs Guide RNA (gRNA) Selection for B2M. In order to identify a wide variety of gRNAs capable of editing the B2M DNA target region, an in vitro transcribed (IVT) gRNA selection was performed. B2M-targeting gRNAs were designed to target exon 1 of the B2M gene. The B2M genome sequence was submitted for analysis using gRNA design software. The resulting list of gRNAs was narrowed down to a list of approximately 200 gRNAs based on the uniqueness of the sequence (only gRNAs with no perfect match to any other position in the genome were selected) and minimal predicted off-targets. This set of gRNAs was in vitro transcribed and transfected into HEK293T cells constitutively expressing Cas9 using MessengerMax. Cells were harvested 48 hours after transfection, genomic DNA was isolated, and cleavage efficiency was assessed using TIDE analysis. Guide RNAs with high indels and low predicted off-target effects were selected for further analysis. Table 3 presents the target sequences of the selected B2M gRNAs.
[0314] [Table 3]
[0315] Selection of B2M gRNA in iPSCs. Three gRNAs (B2M-1, B2M-2, and B2M-3) were used to edit iPSCs. The location of the target sequence for each of these gRNAs is illustrated in FIG. 2. IPSC (TC-1133 cell line, RUDCR, NJ) cells were nucleofected using a Lonza 4D nucleofector and a P3 primary cell kit (Lonza, cat#V4XP-3024) with an RNP mixture of Cas9 (Aldevron, cat#9212-5MG) and gRNA (Synthego) at a molar ratio of 3:1 (gRNA:Cas9) at a final concentration of 125 pmol Cas9 and 375 pmol gRNA. Cells were dissociated using Accutase (Stempro, cat#A1110501) and subsequently resuspended in DMEM / F12 medium (Gibco, cat#11320033), counted using a Cellometer (Nexcellon) and centrifuged. Cells were cultured at 2×10 3 Resuspended in P3 buffer with supplement 1 (4.5:1 ratio) at a concentration of 2 x 10 cells / μL. 5 Cells were combined with the RNP complex, transferred to a nucleofection cuvette (Lonza kit) and nucleofected using program CA-137. For each cuvette, 250 μL of StemFlex medium (Gibco, cat#A3349401) with CloneR (Stem Cell Technologies, cat#05888) (1:10 ratio) was used to resuspend the nucleofected cells. This cell suspension was split into two wells of a vitronectin (Gibco, cat#A14700) coated 24-well plate with an additional 250 μL of StemFlex with CloneR. Cells were allowed to recover for 48 hours in a low-oxygen incubator (37°C, 4% O2, 8% CO2). After 48 hours, genomic DNA was collected from one well of each working replicate using a gDNA isolation kit (Qiagen, cat#69506).
[0316] The isolated gDNA was subjected to PCR to determine the indel frequency. PCR for the relevant regions was performed using Platinum Taq Supermix (Invitrogen, cat#125320176 and Cat#11495017) with B2M primers. Primer sequences are provided in Table 4, and the position of the B2M primers relative to the gRNA target site is shown in Figure 2. Cycling conditions are provided in Table 5.
[0317] [Table 4]
[0318] [Table 5]
[0319] The resulting amplification products were subjected to PCR purification and Sanger sequencing. The results of the Sanger sequencing were entered into Tsunami along with the guide sequences. The percentage and identity of indels were calculated by the software (Figure 3A). B2M-1, B2M-2, and B2M-3 gRNAs had indel frequencies of 2.5% ± 1.1%, 87.6% + 14.1%, and 63.9% + 0.9%, respectively (n = 2). Figures 3B and 3C show the distribution of indel results for B2M-2 (Figure 3B) and B2M-3 gRNA (Figure 3C).
[0320] Cells in replicate wells were maintained to confluence and passaged into successively larger vessels, with the majority of the population transferred to Advanced 20 / 10 / 10 medium (see Table 6) and Laminin-521 (Stem Cell Technologies, cat#77004) for maintenance.
[0321] [Table 6]
[0322] B2M KO IPS clone generation and characterization. Sequence-verified bulk-edited populations (Figure 4A) were single cell sorted into vitronectin-coated 96-well plates using FACS-ARIA (BD Bioscience) and harvested in StemFlex with CloneR. Briefly, cells were dissociated from maintenance flasks using Accutase and resuspended in StemFlex with CloneR. Cells were then counted using a Cellometer and collected at 1 x 10 5 100% PBS / mL. 2 mL of this was filtered through a cell strainer (Falcon, #352235) into a FACS tube and delivered to the operator to sort single cells into individual wells. The seeded single cells were grown in a low-oxygen incubator (37° C., 8% CO2, 4% O2) with medium changes every other day until colonies were large enough to be re-seeded as single cells. When confluent, samples were split for maintenance and gDNA extraction (see above). Clonal identity was confirmed by PCR and Sanger sequencing (see below for details). Table 7 presents the sequences of selected clones around the cut site (deleted and / or inserted sequences are shown in bold).
[0323] [Table 7]
[0324] Clonal sequences were aligned in Snapgene software to determine indel identity and homozygosity. As shown in Figure 4B, eight clones were homozygous for B2M KO, and seven clones were heterozygous for B2M KO. Homozygous clones with the desired edits were expanded and further verified by sequencing and flow cytometry. Initially, clones were maintained in StemFlex medium on vitronectin-coated plates, and then finally transferred to Advanced 20 / 10 / 10 medium and Laminin-521-coated vessels.
[0325] Cells were further maintained on Laminin-521 coated flasks with Advanced 20 / 10 / 10. Edited clones were verified for indel identity by PCR and Sanger sequencing of the B2M region. Knockouts were verified by flow cytometry (see Tables 8 and 9 for list of antibodies utilized) for B2M and HLA-A and Taqman qPCR analysis of B2M expression using standard Taqman protocols (Taqman FastAdvanced Mastermix, ThermoFisher, cat#4444556). Levels of B2M expression for the three B2M KO clones and wild-type (unmodified) cells are presented in Figure 5. All three KO clones tested showed reduced mRNA expression of B2M relative to wild-type cells.
[0326] [Table 8]
[0327] [Table 9]
[0328] RNA extraction was performed using Qiagen RNeasy kits with RNase-free deoxyribonuclease according to the manufacturer's instructions (Qiagen, cat#74104 and 79254). cDNA synthesis was performed using Advanced iScript cDNA synthesis kit for RT-qPCR (BioRad, cat#1725037) according to the manufacturer's instructions. The karyotype status of the clones was assessed by karyotyping service (ThermoFisher) and tracking of known karyotype abnormalities BCL2L1 by ddPCR using ddPCR supermix (no dUTP) for probes (BioRad, cat#1863024; primers in Table 10) according to the manufacturer's instructions with an annealing temperature of 59°C and RPP30 as the reference assay.
[0329] [Table 10]
[0330] The resulting amplification products were gel verified on a precast 2% agarose gel (ThermoFisher, cat#G501802) and submitted for PCR purification and Sanger sequencing. The resulting sequencing files were input into Tsunami software along with the gRNA sequences and control sequence files to determine indel identity and percentage.
[0331] Clones were also confirmed through flow cytometry to be negative for expression of B2M and MHC class I antigens (HLA-A, B, C) with or without interferon-gamma treatment (25 ng / mL, R&D Systems, 285-IF), see Figures 6A-6D.
[0332] Clones were confirmed to retain pluripotency by flow cytometry for pluripotency cell surface markers (Figures 7A-7D). Additional confirmation of pluripotency included Taqman Scorecard (ThermoFisher, cat#A15872), Thermo Pluritest service and trilineage differentiation (see below for full protocol).
[0333] Cells were dissociated and counted as above, then centrifuged and plated at 1x10 in Advanced 20 / 10 / 10 medium containing 2μM Y-27632 (Tocris, cat#1245). 6 The cells were then resuspended to 100 / mL. The resuspended cells were then filtered through a 40 μM filter (Fisherbrand, cat#22363547) and 5 mL of the suspension was seeded into a single well of an ultra-low attachment 6-well dish (Corning, cat#3471). The cells were then placed overnight on an orbital shaker at 98 RPM to form aggregates. After 16 hours, the spent media was removed from each well by carefully swirling the plate to collect the aggregates. 4 mL of fresh Advanced 20 / 10 / 10 was added.
[0334] After a further 24 hours, the cells were differentiated. First, the aggregates were collected in a 50 mL conical tube and centrifuged at 1000 RPM for 1 minute to pellet the aggregates. The medium was aspirated and the aggregates were washed with DMEM / F12. The aggregates were collected again by centrifugation and suspended in 4 mL of the respective differentiation medium before being returned to the dish and shaker. All differentiations used the following basal medium: 480mL IMDM +Glutamax (Gibco, cat#31980030), 480mL F12 +Glutamax (Gibco, cat#31765035), 10mL non-essential amino acids (Gibco, cat#11140076), 5mL 20% BSA (Sigma, cat#A7638-5G), 2mL chemically defined lipids (Gibco, cat#11905031), 1mL 200mM ascorbic acid (Sigma, cat#A4403-100MG), 1mL 10mg / mL holo-transferrin (Sigma, cat#T0665), and 100μL 140μg / ml sodium selenite (Sigma, cat#S5261). To differentiate cells into ectodermal cells, a final concentration of 4 mg / mL insulin (Gibco, cat#12585014), 2 μM A83-01, 2 μM dorsomorphin (Peprotech, cat#8666430) and 2 μM PNU-74654 was used for 2 days. To differentiate cells into mesodermal cells, a final concentration of 1 μg / mL insulin, 0.1 μM PIK-90, 3 μM CHIR99021 (Peprotech, cat#2520691) and 0.5 μM LDN193189 (Peprotech, cat#1062443) was used for 2 days. For endoderm differentiation on day 1, final concentrations of 0.2 μg / mL insulin, 0.1 μM PIK-90, 100 ng / mL activin-A (Peprotech, cat#120-00), 2 μM CHIR00021, and 20 ng / mL FGF basic (Peprotech, cat101-18b) were used. An additional 2 days of differentiation for endoderm were performed with 0.2 μg / mL insulin, 0.1 μM PIK-90, 100 ng / mL activin A, and 0.25 μM LDN193189. Media was changed daily for all differentiations.All were harvested on day 3 for RNA analysis using Taqman Scorecard.
[0335] Example 2: Cell maintenance and proliferation. Maintenance of hESC / hiPSC. Cells of the human embryonic stem cell (hESC) line CyT49 were maintained, cultured, passaged, expanded, and seeded as described in Schulz et al. (2012) PLoS ONE 7(5):e37004. CyT49 cells were dissociated using ACCUTASE® (Stemcell Technologies 07920 or equivalent).
[0336] Human induced pluripotent stem cells (hiPSCs), such as the TC1133 cell line (Lonza), were maintained in StemFlex Complete (Life Technologies, A3349401) on tissue culture plates coated with BIOLAMININ 521 CTG (BioLamina Cat#CT521). Plates were pre-coated with a 1:10 or 1:20 dilution of BIOLAMININ, calcium, magnesium (Life Technologies, 14040133) in DPBS for 2 hours at 37°C. Cells were fed daily with StemFlex medium. For cell passaging, the same cell density as for CyT49 was used. To seed cells as single cells, cells were seeded in StemFlex with 1% RevitaCell™ supplement (100x) (Thermofisher Cat#A2644501) on BIOLAMININ-coated plates.
[0337] Single cell cloning of hPSCs. For single cell cloning, hPSCs (hESCs or hiPSCs) were fed with StemFlex Complete with Revitacell (1x Revitacell final concentration) 3-4 hours prior to dissociation with ACCUTASE®. After dissociation, cells were sorted as single cells per well of BIOLAMININ-coated 96-well tissue culture plates. Single cells were sorted into wells using a WOLF FACS sorter (Nanocellect). Plates were pre-loaded with 100-200 μL StemFlex Complete with Revitacell. Three days after cell seeding, cells were fed with fresh StemFlex and continued to be fed with 100-200 μL of medium every other day. After 10 days of expansion, cells were fed daily with StemFlex until days 12-14. At this point, the plates were dissociated with ACCUTASE® and the collected cell suspension was split 1:2, half into a new 96-well plate for maintenance and half into DNA extraction solution QuickExtract™ DNA extraction solution (Lucigen). After DNA extraction, PCR was performed to assess the presence or absence of the desired gene edits at the targeted DNA locus. Sanger sequencing was used to verify the desired edits.
[0338] Expansion of single cell derived hPSC clones. For CyT49, successfully targeted clones were passaged onto 24-well plates containing pure 10% XF KSR A10H10 medium but coated with BIOLAMININ. After the 24-well stage, CyT49 clones were passaged as described in Schulz et al. (2012) PLoS ONE 7(5):e37004.
[0339] For hiPSCs (TC1133), cells were maintained in StemFlex Complete throughout the routine maintenance process on BIOLAMININ-coated plates with Revitacell during the cloning and passaging steps.
[0340] Example 3: Generation of B2M knockout human pluripotent stem cells (hPSCs) Guide RNA (gRNA) selection for B2M in hPSCs. The three B2M-targeting gRNAs described in Example 1 above were used to target the B2M gene in hPSCs. To evaluate their cleavage efficiency in hPSCs, CyT49 cells were electroporated using a Neon electroporator (Neon transfection kit ThermoFisher Cat#MPK5000) with a ribonucleoprotein (RNP) mixture of Cas9 protein (Biomay) and guide RNA (Synthego) at a molar ratio of 3:1 (gRNA:Cas9) with absolute values of 125 pmol Cas9 and 375 pmol gRNA. To form the RNP complex, gRNA and Cas9 were combined in one vessel with R-buffer (Neon transfection kit) to a total volume of 25 μL and incubated at room temperature for 15 minutes. Cells were dissociated using ACCUTASE®, then resuspended in DMEM / F12 medium (Gibco, cat#11320033), counted using an NC-200 (Chemometec), and centrifuged. A total of 1 × 10 6 Cells were resuspended with RNP complexes and R-buffer was added to a total volume of 125 μL. The mixture was then electroporated with two pulses at 1100V for 30 seconds. After electroporation, the cells were pipetted into an Eppendorf tube filled with StemFlex containing RevitaCell. The cell suspension was then plated onto tissue culture dishes pre-coated with BIOLAMININ 521 CTG at a dilution of 1:20. The cells were cultured for 48 hours in a normoxic incubator (37°C, 8% CO2). After 48 hours, genomic DNA was collected from the cells using QuickExtract (Lucigen, Middleton, WI; Cat#QE09050).
[0341] PCR for the target B2M sequence was performed, and the resulting amplified DNA was assessed for cleavage efficiency by TIDE analysis. PCR for the relevant regions was performed using Platinum Taq Supermix (Invitrogen, cat#125320176 and Cat#11495017). The sequences of the PCR primers are shown in Table 4; the cycling conditions are provided in Table 5. The resulting amplified products were subjected to PCR purification and Sanger sequencing. The Sanger sequencing results were entered into the Tsunami software along with the guide sequence. The percentage and identity of indels were calculated by the software. Specific gRNAs were then selected based on their indel frequency in hPSCs. Figure 8 shows the cleavage efficiency for the three B2M gRNAs.
[0342] The off-targets of the selected gRNAs were evaluated in stem cell-derived DNA using hybrid capture analysis of predicted sites of sequence similarity. B2M-2 and B2M-3 guides showed no detectable off-target effects. B2M-2 gRNA was selected for further cloning due to its high on-target activity and undetectable off-target activity.
[0343] B2M KO hPSC clone generation and characterization. CyT49 hESCs were electroporated using B2M-2 gRNA, and 3 days after electroporation, single cells were sorted into BIOLAMININ 521 CTG-coated 96-well plates containing StemFlex and Revitacell using a WOLF FACS-sorter (Nanocellect). Seeded single cells were grown in a normoxic incubator (37°C, 8% CO2) with medium changes every other day until colonies were large enough to be re-seeded as single cells. When confluent, samples were split for maintenance and genomic DNA extraction.
[0344] The B2M KO status of the clones was confirmed via PCR and Sanger sequencing. The resulting DNA sequences of the targeted B2M regions were aligned in Snapgene software to determine indel identity and homo- or heterozygosity. Clones with the desired edits were expanded and further verified via flow cytometry evaluation for B2M expression (see Table 11 for a list of antibodies utilized). Clones were evaluated with and without interferon-gamma treatment (25ng / mL, R&D Systems, 285-IF). Figure 9A shows B2M expression in wild-type cells, and Figure 9B shows B2M expression in KO cells. The karyotype status of the clones was evaluated via Cell Line Genetics services (Madison, WI) and a normal karyotype was reported.
[0345] [Table 11]
[0346] Clones were confirmed to retain pluripotency by intracellular flow cytometry for the pluripotency markers OCT4 and SOX2. Confirmed pluripotent clones were differentiated into pancreatic endocrine progenitor cells using previously established methods (Schulz et al. (2012) PLoS ONE 7(5):e37004).
[0347] Example 4: Generation of B2M knockout PD-L1 knockin human pluripotent stem cells (hPSCs) Design of the B2M-KO PD-L1-KI strategy. A plasmid was designed to insert PD-L1 (CD274) into the B2M locus such that the start codon of B2M is removed after undergoing homology directed repair (HDR) to insert PD-L1 and abolish the chance of partial B2M expression. Figure 10 shows a schematic diagram of the plasmid, and Table 12 identifies the elements and positions therein. The donor plasmid contained the CAGGS promoter-driven cDNA of PD-L1 flanked by 800 base pair homology arms with sequence identical to the B2M locus around exon 1. The complete sequence of the plasmid is shown in SEQ ID NO:33.
[0348] [Table 12]
[0349] B2M-2 gRNA was used to facilitate insertion of the PD-L1 transgene at the targeted B2M locus. The PD-L1 donor plasmid was introduced together with the RNP complex composed of B2M-targeting gRNA and Cas9 protein. 4 μg of plasmid DNA was delivered with the RNP per million CyT49 cells. Electroporation was performed as described in Example 3. Seven days after electroporation, cells were sorted into BIOLAMININ 521 CTG-coated 96-well plates with StemFlex with Revitacell for PD-L1 surface expression using a WOLF FACS-sorter (Nanocellect). For FACS-sorting, unedited cells served as a negative control. PD-L1 positive cells were selected for sorting and single cell cloning.
[0350] Anti-PD-L1 fluorescent antibody was used to detect PD-L1 surface expression (see Table 11). Plated single cells were grown in a normoxic incubator (37°C, 8% CO2) with medium changes every other day until colonies were large enough to be replated as single cells. When confluent, samples were split for maintenance and genomic DNA extraction.
[0351] Correctly targeted clones were identified via PCR using primers amplifying a region from outside the homology arms of the plasmid to the PD-L1 cDNA insert, allowing for amplification of only the KI-integrated DNA for PD-L1 knock-in (KI) inserts. On-target inserts were tested for zygosity by PCR to assess whether the KI occurred in a heterozygous or homozygous fashion. If a heterozygous clone was identified, the KI negative allele was sent for Sanger sequencing to verify that it contained a B2M-disrupting indel. Correct KI clones with complete B2M disruption (either by KI insertion or indel formation) were expanded in incremental tissue culture format until they reached a population size of 30 million cells. Approximately 10 clones were expanded in this manner and confirmed to be pluripotent by testing for OCT4 and SOX2 via intracellular flow cytometry (Figure 11). Clones that passed the above tests were then further tested for karyotype analysis (Cell Line Genetics) as described below. Additionally, clones were tested for their ability to differentiate into pancreatic endoderm progenitor cells (PECs) via established protocols as follows (Schulz et al. (2012) PLoS ONE 7(5):e37004). Loss of B2M was further confirmed by the lack of expression of B2M in the presence or absence of interferon-gamma treatment (25ng / mL, R&D Systems, 285-IF) via flow cytometry. Figures 12A and 12B show PD-L1 expression in wild-type and B2M KO / PD-L1 KI cells, respectively.
[0352] Example 5: Generation of B2M knockout HLA-E knockin human pluripotent stem cells (hPSCs) Design of the B2M-KO HLA-E-KI strategy. The plasmid design for inserting the HLA-E trimer into the B2M locus was made such that the start codon of B2M was removed after undergoing homology directed repair (HDR) to insert the HLA-E trimer and abolish the chance of partial B2M expression. Figure 13 shows a schematic of the plasmid and Table 13 identifies the elements and positions therein. The HLA-E trimer cDNA was composed of the B2M signal peptide fused to the HLA-G presenting peptide fused to the B2M membrane protein fused to the HLA-E protein without its signal peptide. This trimer design has been previously published (Gornalusse et al. (2017) Nat. Biotechnol. 35(8):765-772). The donor plasmid for HLA-E delivery contains the CAGGS promoter driving expression of the HLA-E trimer flanked by 800 base pair homology arms with sequence identical to the B2M locus around exon 1. The complete sequence of the plasmid is shown in SEQ ID NO:34.
[0353] [Table 13]
[0354] B2M-2 gRNA was used to facilitate the insertion of the HLA-E transgene at the targeted B2M locus. HLA-E donor plasmid was introduced with the RNP complex composed of B2M-targeting gRNA and Cas9 protein. 4 μg of plasmid was delivered with the RNP per million CyT49 cells. Electroporation was performed as described in Example 3. Seven days after electroporation, cells were sorted into BIOLAMININ 521 CTG-coated 96-well plates with StemFlex with Revitacell for HLA-E surface expression using a WOLF FACS-sorter (Nanocellect). For FACS-sorting, unedited cells served as a negative control. HLA-E positive cells were selected for sorting and single cell cloning.
[0355] Anti-HLA-E fluorescent antibodies were used to detect HLA-E surface expression (Table 11). Seeded single cells were grown in a normoxic incubator (37° C., 8% CO2) with medium changes every other day until colonies were large enough to be replated as single cells. When confluent, samples were split for maintenance and genomic DNA extraction.
[0356] Correctly targeted clones were identified via PCR using primers amplifying a region from outside the homology arms of the plasmid to the HLA-E cDNA insert, allowing for the amplification of only the KI-integrated DNA for HLA-E knock-in (KI) inserts. On-target inserts were tested for zygosity by PCR to assess whether the KI occurred in a heterozygous or homozygous fashion. If a heterozygous clone was identified, the KI-negative allele was sent for Sanger sequencing to verify that it contained a B2M-disrupting indel. Correct KI clones with complete B2M disruption (either by KI insertion or indel formation) were expanded in incremental tissue culture format until they reached a population size of 30 million cells. Approximately 10 clones were expanded in this manner and confirmed to be pluripotent by testing for OCT4 and SOX2 via intracellular flow cytometry (Figure 14). Clones that passed the above tests were then further tested for karyotype analysis (Cell Line Genetics). Additionally, clones were tested for their ability to differentiate into pancreatic endoderm progenitor cells (PECs) via established protocols (Schulz et al. (2012) PLoS ONE 7(5):e37004). Loss of B2M was further confirmed by the lack of expression of HLA-A, B, C in the presence or absence of interferon-gamma treatment (50 ng / mL, R&D Systems, 285-IF) via flow cytometry (Figure 15). Figure 16 shows HLA-E expression.
[0357] Example 6: Karyotype analysis of edited clones G-banded karyotype analysis of edited embryonic stem (ES) cells. One million edited ES cells were passaged into T-25 culture flasks containing culture medium (DMEM / F12 + 10% Xeno-free KSR with 10 ng / mL activin and 10 ng / mL heregulin). After overnight culture, three T25 culture flasks were sent to a cytogenetics lab (Cell Line Genetics, Inc.) for karyotype analysis; FISH analysis for chromosomes 1, 12, 17, 20; and array comparative genomic hybridization (aCGH) analysis with a standard 8x60K array. The G-banding results of selected cells electroporated with non-cutting guide ("NCG"), B2M KO clone, B2M HO / PD-L1 HI clone ("V1-A"), and B2M KO / HLA-E KI clone ("V2-A") are shown in Table 14.
[0358] [Table 14]
[0359] Example 7: Differentiation of edited human embryonic stem cells into pancreatic endoderm cells (PECs) Maintenance of edited human embryonic stem cells (ES). Edited human embryonic stem cells at various passage numbers (P38-42) were maintained at 33,000 cells / cm for 4-day passaging in hESM medium (DMEM / F12 + 10% KSR + 10 ng / mL activin A and 10 ng / mL heregulin) with final 10% human AB serum. 2 or 50,000 cells / cm for 3-day passaging 2 was sown in.
[0360] Aggregation of edited human embryonic stem cells for PEC differentiation. Edited ES were dissociated into single cells with ACCUTASE®, followed by centrifugation and resuspending in 2% StemPro (Cat# A1000701, Invitrogen, CA) in DMEM / F12 medium at 1 million cells per ml, for a total of 3.5-4 million cells, using one 850 cm rotation at 8 RPM ± 0.5 RPM.2 ES aggregates derived from edited human embryonic stem cells were differentiated into pancreatic lineages using rotor bottles as described in Schulz et al. (2012) PLoS ONE 7(5):e37004.
[0361] Example 8: Characterization of differentiated pancreatic endoderm cells (PEC) Flow cytometry for FOXA2 and SOX17 at stage 1 (DE) and CHGA, PDX1 and NKX6.1 at PEC stage. Stage 1 aggregates derived from hESC or pancreatic aggregates derived from hESC were washed with PBS and then enzymatically dissociated into single cell suspensions using ACCUMAX™ (Cat#A7089, Sigma, MO) at 37° C. MACS separation buffer (Cat#130-091-221, Miltenyi Biotec, North Rhine-Westphalia, Germany) was added and the suspension was passed through a 40 μm filter and pelleted. For staining of intracellular markers, cells were fixed in 4% (wt / v) paraformaldehyde for 30 min and washed in FACS buffer (PBS, 0.1% (wt / v) BSA, 0.1% (wt / v) NaN3), then cells were permeabilized with Perm buffer (PBS, 0.2% (v / v) Triton X-100 (Cat#A16046, Alfa Aesar, MA), 5% (v / v) normal donkey serum, 0.1% (wt / v) NaN3) for 30 min on ice, followed by washing with wash buffer (PBS, 1% (wt / v) BSA, 0.1% (wt / v) NaN3). Cells were incubated overnight at 4° C. with primary antibodies (Table 15) diluted in blocking buffer (PBS, 0.1% (v / v), Triton X-100, 5% (v / v) normal donkey serum, 0.1% (wt / v) NaN3). Cells were washed in IC buffer and then incubated with the appropriate secondary antibodies for 60 min at 4° C. Cells were washed in IC buffer and then washed in FACS buffer. Flow cytometry data were acquired with a NovoCyte flow cytometer (ACEA Biosciences, Brussels). Data were analyzed using FlowJo software (Tree Star, Inc.). Untreated cells were identified based on forward (low angle) and side (orthogonal, 90°) light scatter. Background was estimated using antibody controls and undifferentiated cells. In the figures, representative flow cytometry plots are shown for one of the subpopulations. Numbers reported in the figures represent the percentage of total cells from the untreated cell gate.
[0362] [Table 15]
[0363] At the DE stage, the population of FOXA2 and SOX17 double positive cells exceeded 90% of the total cells in CyT49 wild-type differentiated cells. PD-L1 KI / B2M KO, HLA-E KI / B2M KO, and B2M KO cells showed comparable percentages of DE compared to wild-type cells (Figures 17A-17B and 18).
[0364] At the PEC stage, flow cytometry was performed for chromogranin (CHGA), PDX1, and NKX6.1. The heterogeneous population at the PEC stage includes pancreatic progenitor cells, early endocrine cells (Figure 19). From the pie chart of the heterogeneous population (Figure 20), the distribution of the cell population of the differentiated edited cells (PD-L1 KI / B2M KO or B2M KO) was very similar to that of the wild-type cells.
[0365] Targeted RNAseq. Targeted RNAseq for gene expression analysis was performed using Illumina TruSeq and a custom panel of oligos targeting 111 genes. The panel contained genes that are markers of developmental stages during pancreatic differentiation. At the end of each differentiation stage, 10 μL of APV (aggregated pellet volume) was collected and extracted using Qiagen RNeasy or RNeasy 96 spin column protocols, including on-column deoxyribonuclease treatment. Quantification and quality control were performed using either a TapeStation coupled with Qubit or a Qiagen QIAxcel. 50-200 ng of RNA was processed according to the Illumina TruSeq library preparation protocol consisting of cDNA synthesis, hybridization of custom oligo pools, washing of bound oligos, extension, ligation, PCR amplification of libraries, and purification of libraries, before quantification and quality control of the resulting dsDNA libraries using either a TapeStation coupled with Qubit or a Qiagen QIAxcel. Libraries were then diluted to a concentration of 4 nM and pooled, followed by further dilution to 10-12 pM before denaturation, spiking in PhiX controls, and loading onto an Illumina MiSeq sequencer. After the sequencing run, initial data analysis was performed automatically by BaseSpace to generate raw read counts for each of the custom probes. Then, for each gene, these read counts were summed for all probes corresponding to that gene by adding one read count (to prevent downstream division by 0). Normalization was performed against gene SF3B2, and reads were typically visualized as fold change relative to stage 0. When data were processed for principal component analysis, normalization was performed using the DEseq method. Selected gene expression was shown in Figure 21. The dynamic expression patterns of FOXA2, CHGA, PDX1, and NKX6.1 from PD-L1 KI / B2M KO or B2M KO cells were similar to wild-type cells.
[0366] Confirmation of B2M and PD-L1 expression at the PEC stage. At the PEC stage, differentiated aggregates were stimulated with or without interferon-gamma (50ng / ml) for 48 hours. Aggregates were washed with PBS and then enzymatically dissociated into single cell suspensions at 37°C using ACCUMAX™ (Cat#A7089, Sigma, MO). MACS separation buffer (Cat#130-091-221, Miltenyi Biotec, North Rhine-Westphalia, Germany) was added and the suspension was passed through a 40μm filter and pelleted. For staining of surface markers, dissociated cells were incubated with fluorescently conjugated antibodies diluted in MACS separation buffer for 20 minutes and subsequently washed in MACS separation buffer. Cells were resuspended in FACS buffer for flow acquisition. Flow cytometry data was obtained by a NovoCyte flow cytometer. As shown in Figures 22A-22F, B2M expression was below the limit of detection in differentiated PECs derived from PD-L1 KI / B2M KO or B2M KO, and PDL1 was expressed in differentiated PECs derived from PD-L1 KI / B2M KO cells.
[0367] Immunophenotype of PEC cells. At the PEC stage, differentiated aggregates were stimulated with or without interferon-gamma (50 ng / ml) for 48 h. Aggregates were collected for MHC class I and II staining. There was no expression of MHC class II at the PEC stage derived from wild-type or edited cells (PD-L1 KI / B2M KO and B2M KO cells) (Figures 23D-23F). Expression of HLA-ABC (MHC class I) was low (1.3% from wild-type) and it was highly regulated upon IFN-γ stimulation. However, HLA-ABC was not expressed even under IFN-γ stimulation in edited cells (PD-L1 KI / B2M KO and B2M KO cells) (Figures 23A-23C).
[0368] Example 9: T cell activation / proliferation assay PEC-differentiated cells were tested for their ability to induce immune responses via an in vitro human T cell activation / proliferation assay. Fresh donor PBMCs were purchased from Hemacare and CD3+ T cells were purified using a pan T cell isolation kit, human (Miltenyi Cat#130-096-535). Isolated T cells were labeled with CellTrace™ CFSE cell proliferation kit protocol (Thermofisher Cat#34554) per manufacturer's instructions and co-incubated with differentiated PECs for 5 days. Dynabeads™ human T-activator CD3 / CD28 for T cell proliferation and activation (Thermofisher Cat#11161D) were used as a positive control to activate T cells. T cells alone were labeled with CFSE and used as a negative control. The percentage of CD3+ CFSE+ cells was measured to assess the percentage of T cell proliferation (Figures 24A-24D). WT PECs induced T cell proliferation above the T cell alone control, whereas PECs derived from B2M KO and B2M KO / PD-L1 KI CyT49 did not induce T cell proliferation above the T cell alone control, indicating low immunogenicity of the edited cells.
Claims
1. 1. A method for generating a universal donor cell, comprising:
1. A method comprising genetically modifying a cell by introducing into the genome of said cell an insertion of a polynucleotide encoding a tolerogenic factor, which is programmed death-ligand 1 (PD-L1), wherein the genetic modification comprises delivering at least one RNA-guided endonuclease system comprising a CRISPR nuclease and a guide RNA that targets a site within a beta-2-microglobulin (B2M) locus, and the polynucleotide encoding the tolerogenic factor is flanked by (a) a nucleotide sequence set forth in SEQ ID NO: 13 having sequence homology to a region located to the left of a site within the B2M locus, and (b) a nucleotide sequence set forth in SEQ ID NO: 19 having sequence homology to a region located to the right of a site within the B2M locus, wherein the B2M locus is cleaved at the target site, and a polynucleotide encoding PD-L1 is inserted into the B2M locus within 50 base pairs of a site within the B2M locus, thereby disrupting the B2M gene and generating a universal donor cell; The method, wherein the genetically modified cells are pluripotent stem cells (PSCs), embryonic stem cells (ESCs), adult stem cells (ASCs), induced pluripotent stem cells (iPSCs), or hematopoietic stem or progenitor cells (HSPCs).
2. The method of claim 1, wherein the universal donor cells have increased immune evasion and / or cell survival compared to unmodified cells.
3. The method of claim 1 or 2, wherein the site targeted by the guide RNA comprises at least one nucleic acid sequence of SEQ ID NO: 1 to 3.
4. The method of any one of claims 1 to 3, wherein the site targeted by the guide RNA comprises the nucleic acid sequence of SEQ ID NO:
2.
5. The method according to any one of claims 1 to 4, wherein the polynucleotide encoding the tolerogenic factor further comprises an exogenous promoter, and the polynucleotide encoding the tolerogenic factor is operably linked to the exogenous promoter.
6. 6. The method of claim 5, wherein the exogenous promoter is a constitutive, inducible, time-specific, tissue-specific, or cell type-specific promoter.
7. The method of claim 6 , wherein the exogenous promoter is a CAG promoter.
8. The method of any one of claims 1 to 7, wherein the polynucleotide encoding the tolerogenic factor comprises a vector.
9. The method of claim 8, wherein the vector is a plasmid vector comprising the nucleic acid sequence set forth in SEQ ID NO:
33.
10. The method of any one of claims 1 to 9, wherein the CRISPR nuclease is a Cas9 nuclease.
11. 11. The method of claim 10, wherein the Cas9 nuclease is S. pyogenes Cas9.
12. The method of any one of claims 1 to 11, wherein the CRISPR nuclease comprises an N-terminal nuclear localization signal (NLS) and / or a C-terminal NLS.
13. 13. The method of any one of claims 1 to 12, wherein the CRISPR nuclease and the guide RNA are present in a 1:1 ratio by weight.
14. 14. The method of any one of claims 1 to 13, wherein the CRISPR nuclease is pre-complexed with one or more guide RNAs as a ribonucleoprotein particle (RNP).
15. The method of any one of claims 1 to 14, wherein the universal donor cell is a mammalian cell.
16. The method of claim 15, wherein the mammalian cell is a human cell.
17. The method of any one of claims 1 to 16, wherein the universal donor cells are capable of differentiating into lineage-restricted progenitor cells or fully differentiated somatic cells.
18. 18. The method of claim 17, wherein the lineage-restricted progenitor cells are pancreatic endodermal progenitor cells, pancreatic endocrine progenitor cells, mesenchymal progenitor cells, muscle progenitor cells, blast cells, or neural progenitor cells.
19. 18. The method of claim 17, wherein the fully differentiated somatic cell is an endocrine cell, such as a pancreatic beta cell, an epithelial cell, an endodermal cell, a macrophage, a liver cell, an adipocyte, a kidney cell, a blood cell, or a cell of the immune system.
Citation Information
Patent Citations
Genomic engineering of pluripotent cells
WO2017079673A1
